Original Article
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
N Engl J Med 1995; 333:1540-1545December 7, 1995
- Abstract
Background
High-dose chemotherapy followed by autologous bone marrow transplantation is a therapeutic option for patients with chemotherapy-sensitive non-Hodgkin's lymphoma who have relapses. In this report we describe a prospective randomized study of such treatment.
Methods
A total of 215 patients with relapses of non-Hodgkin's lymphoma were treated between July 1987 and June 1994. All patients received two courses of conventional chemotherapy. The 109 patients who had a response to chemotherapy were randomly assigned to receive four courses of chemotherapy plus radiotherapy (54 patients) or radiotherapy plus intensive chemotherapy and autologous bone marrow transplantation (55 patients).
Results
The overall rate of response to conventional chemotherapy was 58 percent; among patients with relapses after chemotherapy, the response rate was 64 percent, and among those with relapses during chemotherapy, the response rate was 21 percent. There were three deaths from toxic effects among the patients in the transplantation group, and none among those in the group receiving chemotherapy without transplantation. The two groups did not differ in terms of prognostic factors. The median follow-up time was 63 months. The response rate was 84 percent after bone marrow transplantation and 44 percent after chemotherapy without transplantation. At five years, the rate of event-free survival was 46 percent in the transplantation group and 12 percent in the group receiving chemotherapy without transplantation (P = 0.001), and the rate of overall survival was 53 and 32 percent, respectively (P = 0.038).
Conclusions
As compared with conventional chemotherapy, treatment with high-dose chemotherapy and autologous bone marrow transplantation increases event-free and overall survival in patients with chemotherapy-sensitive non-Hodgkin's lymphoma in relapse.
Media in This Article
Figure 2
Kaplan–Meier Curves for Overall Survival of Patients in the Transplantation and Conventional-Treatment Groups.Figure 1
Kaplan–Meier Curves for Event-free Survival of Patients in the Transplantation and Conventional-Treatment Groups.Article Activity
- Article
It is generally agreed that patients with intermediate- or high-grade non-Hodgkin's lymphoma who have a relapse after initial therapy have a poor prognosis.1,2 A retrospective study in 1984 from France and England showed a clear relation between the responsiveness of the lymphoma to treatment and the outcome.3 In 1987, the combination of high-dose chemotherapy and autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma in relapse was considered promising but experimental and appropriate for use only at research centers.1 The value of that treatment remains an open question, because conventional salvage treatment without autologous bone marrow transplantation can induce lengthy remissions; long-term survival after a relapse has been reported with at least five different chemotherapy regimens.4-8
In a preliminary study, our group (the Parma Group, formed in 1986 during a meeting in Parma, Italy) found that salvage chemotherapy followed by radiotherapy of the involved field, high-dose chemotherapy, and autologous bone marrow transplantation induced prolonged, but unmaintained, remissions in 40 percent of patients who had treatment-sensitive lymphomas in relapse. The death rate from toxic effects among these patients was only 10 percent.9 We now report the results of a prospective randomized trial of this treatment.10
Methods
Patients
We enrolled a total of 215 patients with non-Hodgkin's lymphoma of intermediate grade (163 patients) or high grade (52 patients) in relapse. The patients were 18 to 60 years old at the time of the first relapse (188 patients) or the second relapse (27 patients). The patients were enrolled between July 1987 and June 1994 at 51 participating centers (see the Appendix).
To be eligible for enrollment, patients had to have received previous treatment with a doxorubicin-containing regimen.10 All patients had a complete response to an initial induction regimen, with the response maintained for at least four weeks. Relapses during and after therapy were defined by the investigators at the participating centers. Patients with central nervous system or bone marrow involvement at the time of the relapse were excluded. Informed consent was obtained from each patient according to the Parma protocol and the rules of each participating center and country.
All patients were given dexamethasone, cisplatin, and cytarabine (DHAP).5 After one course of DHAP, bone marrow was harvested (except in 41 patients with clearly progressive disease) while the patients were under general anesthesia. The bone marrow was frozen,9 unless marrow had been stored previously (in the case of 24 patients). Bone marrow–biopsy specimens obtained at the time of harvesting were normal in all patients. None of the patients received hematopoietic growth factors before the bone marrow was harvested. Peripheral-blood stem cells were not collected. A second course of DHAP was given beginning on day 1 after the harvesting. Twenty days later, the stage of the disease was reevaluated according to the sites involved when the first course of DHAP therapy was initiated. Patients with complete or partial responses were considered to have relapses of chemotherapy-sensitive lymphoma and were eligible for random assignment to one of the treatment groups.
Randomization was performed as early as possible between day 20 and day 60 after the initiation of the second course of DHAP. Interactive computerized procedures were used to monitor data at the time of enrollment and randomization. Patient assignments were stratified according to center, and the computer assigned each patient to a treatment group on the basis of a permuted-block design. All data were checked for validity and coherence by the coordinating center. Errors and missing values were reported to the investigators for correction or confirmation. The plausibility of the data and consistency among variables were checked. On-site monitoring was not performed systematically, but before the final analysis, an effort was made to obtain missing data.
Treatment
Eligible patients were randomly assigned to receive autologous bone marrow transplantation or conventional treatment. The conditioning regimen in the transplantation group consisted of carmustine, etoposide, cytarabine, cyclophosphamide, and mesna (BEAC), with or without radiotherapy of the involved field, followed by bone marrow transplantation. Radiotherapy was part of the transplantation protocol and was indicated if the sites of bulky disease at the time of relapse were at least 5 cm in diameter or if there were extranodal T3 or T4 lesions (according to the classification of the European Organization for Research and Treatment of Cancer).9 The total dose of radiation was 26 Gy, given in fractions of 1.3 Gy each, delivered twice daily with at least four hours between the two treatments. An involved field was defined according to the Ann Arbor staging system11 and the diameter of bulky disease at the time of the relapse (i.e., during the enrollment phase), not at the time of randomization.9 BEAC was administered 48 hours after the completion of radiotherapy, on days 21 through 60 after the second course of DHAP.
The regimen consisted of 300 mg of carmustine per square meter of body-surface area (administered intravenously for 30 to 60 minutes) on day 1; a total daily dose of 200 mg of etoposide per square meter (100 mg per square meter given intravenously for 30 to 60 minutes twice daily) on days 2 through 5; a total daily dose of 200 mg of cytarabine per square meter (100 mg per square meter given intravenously for 30 minutes twice daily) on days 2 through 5; a total daily dose of 35 mg of cyclophosphamide per kilogram of body weight (given as a short infusion for 60 minutes) on days 2 through 5; and a total daily dose of 50 mg of mesna per kilogram (optional) on days 2 through 5 (given intravenously in six fractions every 4 hours for 30 minutes). Autologous bone marrow transplantation was performed through a central line 48 hours after the last dose of etoposide, with a minimum of 100 million nucleated cells per kilogram injected. Patients received care in single rooms according to the protocol for supportive care at each participating center.10
The conventional treatment consisted of four additional courses of DHAP given at intervals of three to four weeks, followed, if no progression occurred, by radiotherapy of the involved field according to the same definition of bulky disease used at the time of enrollment (i.e., >5 cm). The radiotherapy was administered as complementary treatment. The dose of radiation was 35 Gy delivered in 20 fractions of 1.75 Gy per fraction.
After randomization, each patient was evaluated in the group to which he or she had been assigned, even if the treatment was incomplete. The objective was to compare groups, not treatments. In both groups, additional treatment was allowed if the assigned treatment had failed. Such additional treatment included high-dose chemotherapy and autologous bone marrow transplantation for patients in the conventional-treatment group. No specific conditioning regimen was recommended at this stage.
Statistical Analysis
Survival curves were calculated according to the Kaplan–Meier method12 and compared by the two-sided log-rank test,13 with the use of the Lifetest procedure in the SAS statistical package. Differences were considered significant if the P value was less than 0.05. Other comparisons were performed with the chi-square and Fisher's exact tests.14
An event was defined as a relapse, evidence of disease progression, or death, whatever the cause. The date of the first event was used in calculating event-free survival.
A steering committee and policy board (see the Appendix) were set up in 1987 to monitor the interim analysis. The first analysis was performed in June 1990 to detect any abnormal toxic effects in the transplantation group (>15 percent).9 A second analysis was performed in June 1992, with differences considered significant if the P value was less than 0.01. The policy board decided to stop the study in June 1994, before further analysis of the data had been performed.
Results
Enrollment and Treatment
A total of 215 patients were enrolled in the study. There were 126 men and 89 women, with a median age of 43 years. A total of 163 patients had intermediate-grade lymphoma, and 52 had high-grade lymphoma. A central review of the pathological findings was not mandatory. Forty-three percent of the patients had elevated serum lactic dehydrogenase values at the time of enrollment.
The rate of response to the initial doxorubicin-containing regimen was 58 percent. Fifty-three patients (25 percent) had complete responses and 72 (34 percent) had partial responses. Among the 187 patients who had relapses after therapy with the doxorubicin-containing regimen, 64 percent had responses to two courses of DHAP. Among the 28 patients who had relapses during therapy with the doxorubicin-containing regimen, the rate of response to DHAP was 21 percent.
Ninety patients were excluded before randomization because they did not have a response to DHAP, and 16 of the 125 patients with responses (8 with complete responses and 8 with partial responses) were not included for reasons defined in the protocol.
The remaining 109 patients were randomly assigned to high-dose chemotherapy, irradiation of the involved field (if indicated), and autologous bone marrow transplantation (55 patients) or conventional treatment (54 patients). Of these 109 patients, 95 were having a first relapse, and 14 were having a second relapse; all 109 had had complete responses after the first-line therapy. The serum concentration of lactate dehydrogenase was elevated in 36 of the 105 randomized patients (34 percent) for whom data were available at the time of enrollment (Table 1Table 1
Base-Line Characteristics of the 109 Patients with Non-Hodgkin's Lymphoma Randomly Assigned to Autologous Bone Marrow Transplantation or Conventional Treatment.). At the time of randomization, the lactate dehydrogenase concentration was still abnormal in 20 patients in the transplantation group and 21 in the conventional-treatment group. Of the 109 patients, 45 had complete responses (41 percent) and 64 had partial responses (59 percent) at the time of randomization.The time of relapse (during or after therapy), histologic type of lymphoma, and number of second relapses (nine in the conventional-treatment group and five in the transplantation group, P = 0.24) were similar in the two groups (Table 1). The site of the relapse, proportion of patients with elevated lactate dehydrogenase concentrations at the time of the relapse (36 percent in the transplantation group and 33 percent in the conventional-treatment group), and size of the tumor at the time of the relapse were also similar in the two groups.
Six of the 55 patients randomly assigned to high-dose chemotherapy and autologous bone marrow transplantation did not undergo transplantation but were analyzed with the other patients in this group.15 One of the six died early in the course of a relapse, before receiving BEAC. Two had progressive disease before receiving BEAC, were treated with other chemotherapeutic regimens, and died. Another patient who had progressive disease before the administration of BEAC received salvage treatment and then BEAC, had a relapse four months later, received another rescue treatment, and survived. The other two patients received DHAP: one because of a cardiac problem after randomization and before the administration of BEAC, and one because no stem cells were present in the bone marrow before the initiation of BEAC. These two patients underwent autologous bone marrow transplantation outside the protocol after relapse (with a second harvest performed in one), and both died.
Overall and Event-Free Survival
Thus, 49 patients received high-dose chemotherapy and autologous bone marrow transplantation. Three (6 percent) died from toxic effects: one from septic shock on day 63 after transplantation, one from a fungal infection on day 97, and one from cardiac toxicity on day 83. An additional patient, who was in complete remission, died from pulmonary infection on day 406 after transplantation (this death was classified as due to late toxicity). Twenty-two of the 55 patients in the transplantation group received radiotherapy. Two of these patients had relapses before receiving BEAC. Morbidity after treatment with high-dose chemotherapy and autologous bone marrow transplantation was high, with 1 case of septic shock and 30 episodes of bacterial infection (septicemia in 17), 8 of viral infection, 6 of fungal infection, 5 of renal toxicity, 4 of hepatic toxicity (grade 3 in 2 patients), and 3 of pneumonitis. Twenty-seven patients had mucositis (grade 3 in 7 patients and grade 4 in 2), 16 had diarrhea (grade 3 in 6), and 1 had grade 4 cardiac toxicity.
None of the 54 patients randomly assigned to the conventional-treatment group died from toxic effects of treatment, and 37 patients received at least three courses of DHAP. Only 12 of the 54 patients received radiotherapy of the involved field after four additional courses of DHAP (essentially because 26 patients had relapses during the four courses of DHAP and before receiving radiotherapy). Morbidity was lower in this group than in the transplantation group, with one case of septic shock and six episodes of bacterial infection (septicemia in three), two of viral infection, one of fungal infection, three of pneumonitis, and one of hepatic toxicity. Four patients had mucositis, three had diarrhea (grade 3 in one patient), and two had cardiac toxicity (grade 1 in both). Only renal toxicity (14 cases, 1 of which was grade 3) was more frequent than in the transplantation group.
The median follow-up period was 63 months. The response rate was 84 percent after bone marrow transplantation and 44 percent after chemotherapy without transplantation. The overall survival at five years in the group of 109 randomized patients was 42 percent, as compared with 45 percent in the group of 16 patients excluded from randomization (5 of the 8 survivors had no evidence of disease) and 11 percent in the group of 90 patients without initial responses to chemotherapy (P<0.001). The rate of event-free survival was 46 percent in the transplantation group and 12 percent in the conventional-treatment group (P = 0.001) (Figure 1Figure 1
Kaplan–Meier Curves for Event-free Survival of Patients in the Transplantation and Conventional-Treatment Groups.). At five years, the overall survival was 53 percent in the transplantation group and 32 percent in the conventional-treatment group (P = 0.038) (Figure 2Figure 2Kaplan–Meier Curves for Overall Survival of Patients in the Transplantation and Conventional-Treatment Groups.).Relapses
Twenty-six of the patients who received high-dose chemotherapy and autologous bone marrow transplantation had relapses. There was no significant difference in the proportion with relapses between the subgroup of patients who had received radiotherapy of the involved field (22 patients, 8 with relapses) and the subgroup who had not received radiotherapy (33 patients, 18 with relapses; P = 0.19). Relapses occurred at the primary site of the disease at the time of the first relapse in 4 of the 22 patients who underwent irradiation and in 12 of the 33 who did not (P = 0.15).
In the conventional-treatment group, 45 patients had relapses, also with no statistical difference between those who received radiotherapy of the involved field (12 patients, 10 with relapses) and those who did not (42 patients, 35 with relapses; P = 0.66). Relapses occurred at the primary site of disease at the time of the first relapse in 5 of the 12 patients who underwent irradiation and in 26 of the 42 who did not (P = 0.21).
Transplantation in the Conventional-Treatment Group
Among the 45 patients in the conventional-treatment group who had relapses, 24 did not have at least a partial response to reinduction therapy, and 3 did not undergo autologous bone marrow transplantation, despite a previous response to a rescue protocol. Eighteen of the 45 patients who had relapses with progressive disease subsequently were treated with a high-dose regimen of chemotherapy and bone marrow transplantation, as allowed in the protocol. Sixteen of these 18 patients underwent induction chemotherapy according to a conventional rescue protocol (MIME [mitoguazone, ifosfamide, methotrexate, and etoposide] in 7, and other treatments in 9). The conditioning regimen was BEAC in eight patients, cyclophosphamide and total-body irradiation in five, and other treatments in five (data not shown). Fourteen of the 18 died, and 2 survived with relapses; only 2 were alive and free of disease 333 and 1911 days after autologous bone marrow transplantation.
Discussion
This study demonstrates a significantly higher survival rate after high-dose chemotherapy and autologous bone marrow transplantation than after conventional chemotherapy in adults with relapses of chemotherapy-sensitive, intermediate- or high-grade non-Hodgkin's lymphoma. Since we selected patients who were optimally suited for chemotherapy, the result in the conventional-treatment group is disappointing. Furthermore, 11 of the 20 patients still alive at the time of the analysis had progressive disease. These results are similar to those reported by Bosly et al. in a nonrandomized, retrospective study.8
One patient had a relapse 26 months after undergoing autologous bone marrow transplantation. On review the tumor was found to be a small lymphocytic follicular lymphoma, at the time of both this relapse and the initial relapse, not an intermediate-grade, diffuse, mixed-cell type, as originally diagnosed. The patient died 53 months after the transplantation.16 In another patient, who had a relapse at 66 months, the disease was diagnosed after a review of the slides (performed by Dr. D.D. Weisenburger, Omaha, Nebr.) as diffuse, large-cell non-Hodgkin's lymphoma at the time of the initial diagnosis and the first and second relapses. This patient survived.
The prognosis is poor for patients with intermediate- or high-grade non-Hodgkin's lymphoma who have a relapse after a complete remission, regardless of whether any further treatment is given.6,17-19 The most important prognostic factor is the duration of the remission.17 Second complete remissions do occur, however, after further treatment with combination chemotherapy at standard doses, and 10 percent of patients survive for long periods.17,20-22 Cures with high-dose chemotherapy and autologous bone marrow transplantation were first reported by Appelbaum et al.23; this approach, however, is restricted to a minority of patients in relapse, since it cannot be used in patients who are elderly (i.e., older than 60 to 65 years).17
We believe that patients with chemotherapy-sensitive lymphomas in relapse are most likely to have good results with additional chemotherapy.2,3 In our study we selected the patients most likely to benefit from either type of treatment: those younger than 60 years with previous complete responses, no central nervous system or bone marrow involvement, and previous responses to a conventional rescue protocol. Because of these stringent selection criteria, only 129 patients were enrolled between July 1987 and November 1989. Only 43 patients were enrolled between December 1989 and November 1991, because 29 of the 51 participating centers had stopped enrolling patients in the study. Only 18 centers were still enrolling patients after November 1991, and the policy board stopped the study in June 1994 because of the low rate of accrual. The rates of response and survival did not differ significantly among these three periods of enrollment.
The two groups of randomized patients were similar with regard to prognostic factors. Only 22 of 88 patients who could be evaluated had an intermediate or high tumor burden, and only 36 of 105 had high lactate dehydrogenase levels. The six patients with intermediate-grade, follicular, large-cell lymphoma16 were equally distributed in the two groups. Only two patients (both in the conventional-therapy group) had lymphoblastic lymphoma.24 We thus succeeded in selecting a group of patients with favorable prognostic indicators in order to compare high-dose chemotherapy and autologous bone marrow transplantation with conventional therapy under the best possible conditions for the conventional approach.16-19,22,25,26
The rates of mortality from toxic effects and morbidity were higher in the transplantation group than in the conventional-treatment group. Future studies should be conducted to determine whether toxicity can be reduced by the use of peripheral-blood stem cells and growth factors.17,27,28 Some unanswered questions about the management of relapses of lymphoma concern the roles of total-body irradiation (although retrospective studies indicate no marked effect29), bone marrow purging and allogeneic marrow transplantation,28,30-32 and peripheral-blood stem cells in increasing survival and reducing relapses and toxicity.22,33
We conclude that radiotherapy of the involved field and BEAC followed by autologous bone marrow transplantation is the best available treatment for patients with relapses of chemotherapy-sensitive, intermediate- or high-grade non-Hodgkin's lymphoma without bone marrow or central nervous system involvement.
Supported by grants from the Ligue Nationale de Lutte contre le Cancer (Ligues Départementales de la Haute Savoie, Saône et Loire, Rhône, Ain, and Ardèche), the University of Nebraska Medical Center, and the Programme Hospitalier de Recherche Clinique.
We are indebted to Zora Abdelbost, head of the data-center staff in Lyon; to Dr. Thomas Bachelot, Dr. Frédéric Gomez, and Elisabeth Heseltine for exceptional assistance in conducting this study; and to Yves Alamercery and Jean Maupas (Clinical Pharmacology Unit, Lyon), who were responsible for the data-processing system.
Source Information
From the Department of Medical Oncology, Bone Marrow Transplantation and Biostatistics Unit, Centre Léon Bérard, Lyon, France (T.P., P.B., F.C.); Universita degli Studi La Sapienza, Rome (C. Guglielmi, F.M.); the Doctor Daniel Den Hoed Cancer Center, Rotterdam, the Netherlands (A.H.); Antonie Van Leeuwenhoek Huis, the Netherlands Cancer Center Institute, Amsterdam (R.S.); the Academic Medical Center, Amsterdam (H.V.D.L.); Institut Jules Bordet, Brussels, Belgium (D.B.); University Hospital Dijkzigt, Rotterdam, the Netherlands (P.S.); Hôpital Saint Louis, Paris (C. Gisselbrecht); Hôpital Jean Minjoz, Besançon, France (J.-Y.C.); Centre Hospitalier Régional Universitaire de Nantes, Hôpital de l'Hôtel Dieu, Nantes, France (J.-L.H.); and Centre Hospitalier Lyon-Sud, Pierre Benite, France (B.C.).
Address reprint requests to Prof. Philip at the Centre Régional de Lutte contre le Cancer Léon Bérard, 28 rue Laënnec, 69373 Lyon CEDEX 08, France.
Appendix
The Parma study group consisted of the following centers and investigators: Peter MacCallum Cancer Institute, Melbourne, Australia: I. Cooper; St. Vincent Hospital, Sydney, Australia: J.C. Biggs; Academic Hospital, Brussels, Belgium: R. Schots and B. Van Camp; Institut Jules Bordet, Brussels, Belgium: D. Bron; University Ziekenhuis, Edegem, Belgium: R. De Bock and Z. Berneman; Clinique de Mont Godine, Yvoir, Belgium: A. Bosly and C. Chatelain; Hôpital de la Durance, Avignon, France: G. Lepeu; Hôpital Jean Minjoz, Besancon, and Centre Hospitalier Général Louis Pasteur, Colmar, France: J.Y. Cahn, E. Deconinck, and B. Audhuy; Hôpital Antoine Béclère, Clamart, France: G. Tertian and F. Boue; Hôpital Beaujon, Clichy, France: E. Attassi Dumont and J.F. Bernard; Centre Régional de Lutte contre le Cancer (CRLCC) Jean Perrin, Clermont Ferrand, France: M. Legros and F. Mayer; Hôpital Henri Mondor, Creteil, France: C. Haioun; CRLCC George Francois Leclerc, Dijon, France: P. Fargeot; Centre Hospitalier Lyon Sud and Hôpital Edouard Herriot, Lyon, France: B. Coiffier and C. Sebban; CRLCC Léon Bérard, Lyon, France: T. Philip, P. Biron, I. Philip, and J.Y. Blay; CRLCC Institut Paoli Calmettes, Marseille, and Centre Hospitalier Universitaire (CHU) Hôpital Saint Eloi, Montpellier, France: D. Maraninchi, A.M. Stoppa, and V. Faucherre; CHU Brabois, Nancy, France: F. Witz; CHU Hôtel Dieu, Nantes, France: J.L. Harousseau and L. Bataille; CRLCC Antoine Lacassagne, Nice, France: A. Thyss; Hôpital Saint Louis, Paris: C. Gisselbrecht; CHU François Magendie, Pessac, and Centre Hospitalier Régional (CHR) Sainte Andrée, Bordeaux, France: B. David, G. Marit, and M. Longy; CHU La Miletrie, Poitiers, France: F. Guilhot; Hôpital Robert Debré, Reims, France: B. Pignon; CHU Pontchaillou, Rennes, France: C. Dauriac; CRLCC Henri Becquerel, Rouen, France: H. Tilly; CRLCC René Huguenin, St. Cloud, France: M. Janvier; CHU Purpan, Toulouse, France: G. Laurent; CHU Bretonneau, Tours, France: P. Colombat; CHU Paul Brousse, Villejuif, France: J.L. Misset, P. Ribaud, M.P. Lemonnier, and M. Di Palma; Klinikum Charlottenburg, Berlin, Germany: W. Siegert; Universita degli Studi Bari Policlinico, Bari, Italy: V. Pavone and V. Liso; Ospedale Maggiore, Cremona, Italy: A. Porcellini and A. Manna; Università Di Parma, Parma, Italy: V. Rizzoli and L. Mangoni; Ospedale Maria Delle Croci, Ravenna, Italy: G. Rosti; Università La Sapienza, Rome: C. Guglielmi, F. Mandelli, M. Martelli, and G. Meloni; Academic Medical Center, Amsterdam: H. Van Der Lelie; Antoni Van Leeuwenhoek, Amsterdam: R. Somers; University Hospital, Groningen, the Netherlands: G.W. Van Imhoff; University Hospital, Leiden, the Netherlands: J.C. Kluin Nelemans; University Hospital, Maastricht, the Netherlands: P. Hupperets; Doctor Daniel Den Hoed Cancer Center, Rotterdam, the Netherlands: A. Hagenbeek; University Hospital Dijkzigt, Rotterdam, the Netherlands: P. Sonneveld; Leyenburg Hospital, The Hague, the Netherlands: H. Girrits and P.W. Wijermans; Hospital de la Princesa, Madrid: J. Fernandez-Ranada; Akademic Sjukhuset, Uppsala, Sweden: B. Simonsson; St. George's Hospital, London: J. Mansi; Royal South Hants Hospital, Southampton, United Kingdom: J.W. Sweetenham; Royal Marsden Hospital, Sutton Surrey, United Kingdom: D. Cunningham; M.D. Anderson Hospital, Houston: F. Cabanillas; University of Arkansas, Little Rock: S. Jagannath; and University of Nebraska, Omaha: J.O. Armitage.
Policy board: D.L. Longo, National Cancer Institute, Frederick, Md.; K.G. Blume, Stanford University Hospital, Stanford, Calif.; E. Gluckman, Hôpital Saint Louis, Paris; C. Griscelli, Hôpital Necker, Paris; D.W. Van Bekkum, Radiobiological Institute, Rijswijk, the Netherlands; and C. Bernasconi, Policlinico San Matteo, Pavia, Italy.
- References
References
1
Rosenberg SA . Autologous bone marrow transplantation in non-Hodgkin's lymphoma. N Engl J Med 1987;316:1541-1542
Full Text | Web of Science | Medline2
Philip T ,Armitage JO ,Spitzer G , et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-1498
Full Text | Web of Science | Medline3
Philip T ,Biron P ,Maraninchi D , et al. Role of massive chemotherapy and autologous bone-marrow transplantation in non-Hodgkin's malignant lymphoma. Lancet 1984;1:391-391
CrossRef | Web of Science | Medline4
Cabanillas F ,Hagemeister FB ,McLaughlin P , et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987;5:407-412
Web of Science | Medline5
Velasquez WS ,Cabanillas F ,Salvador P , et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-122
Web of Science | Medline6
Velasquez WS ,McLaughlin P ,Tucker S , et al. ESHAP -- an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-1176
Web of Science | Medline7
Cabanillas F ,Hagemeister FB ,Bodey GP ,Freireich EJ . IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982;60:693-697
Web of Science | Medline8
Bosly A ,Coiffier B ,Gisselbrecht C , et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992;10:1615-1623
Web of Science | Medline9
Philip T ,Chauvin F ,Armitage J , et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991;77:1587-1592
Web of Science | Medline10
Philip T ,Chauvin F ,Bron D , et al. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol 1991;2:Suppl 1:57-64
Web of Science | Medline11
Carbone PP ,Kaplan HS ,Musshoff K ,Smithers DW ,Tubiana M . Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861
Web of Science | Medline12
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science13
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline14
Freeman DH. Applied categorical data analysis. Vol. 79 of Statistics: textbooks and monographs. New York: Marcel Dekker, 1987.
15
Lewis JA ,Machin D . Intention to treat -- who should use ITT? Br J Cancer 1993;68:647-650
CrossRef | Web of Science | Medline16
Bartlett NL ,Rizeq M ,Dorfman RF ,Halpern J ,Horning SJ . Follicular large-cell lymphoma: intermediate or low grade? J Clin Oncol 1994;12:1349-1357
Web of Science | Medline17
Armitage JO . Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328:1023-1030
Full Text | Web of Science | Medline18
Shipp MA . Prognostic factors in aggressive non-Hodgkin's lymphoma: who has “high-risk” disease? Blood 1994;83:1165-1173
Web of Science | Medline19
The International Non-Hodgkin's Lymphoma Prognostic Factors Project
Full Text | Web of Science | Medline20
Gisselbrecht C ,Bosly A ,Lepage E , et al. Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review. Ann Oncol 1993;4:Suppl 1:7-13
Medline21
Philip T ,Biron P . Role of high-dose chemotherapy and autologous bone marrow transplantation in the treatment of lymphoma. Eur J Cancer 1991;27:320-322
CrossRef | Web of Science | Medline22
Vose JM ,Anderson JR ,Kessinger A , et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1846-1851
Web of Science | Medline23
Appelbaum FR ,Herzig GP ,Ziegler JL ,Graw RG ,Levine AS ,Deisseroth AB . Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978;52:85-95
Web of Science | Medline24
Freedman AS ,Nadler LM . Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? J Clin Oncol 1993;11:1841-1843
Web of Science | Medline25
Rapoport AP ,Rowe JM ,Kouides PA , et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993;11:2351-2361
Web of Science | Medline26
Saez R ,Dahlberg S ,Appelbaum FR , et al. Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study. Hematol Oncol 1994;12:75-85
CrossRef | Web of Science | Medline27
Bonadonna G . Modern treatment of malignant lymphomas: a multidisciplinary approach? The Kaplan Memorial Lecture. Ann Oncol 1994;5:Suppl 2:5-16
Medline28
Jones HM ,Jones SA ,Watts MJ , et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994;12:1693-1702
Web of Science | Medline29
Weaver CH ,Petersen FB ,Appelbaum FR , et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994;12:2559-2566
Web of Science | Medline30
Ratanatharathorn V ,Uberti J ,Karanes C , et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994;84:1050-1055
Web of Science | Medline31
Anderson JE ,Litzow MR ,Appelbaum FR , et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993;11:2342-2350
Web of Science | Medline32
Chopra R ,Goldstone AH ,Pearce R , et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992;10:1690-1695
Web of Science | Medline33
Peterson BA . The role of transplantation in non-Hodgkin's lymphoma. J Clin Oncol 1994;12:2524-2526
Web of Science | Medline
- Citing Articles (545)
Citing Articles
1
Murali Janakiram, Venu K. Thirukonda, Matthew Sullivan, Adam M. Petrich. (2012) Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. Current Treatment Options in Oncology
CrossRef2
Nicolas Mounier, Christian Gisselbrecht. (2012) Relapses, treatments and new drugs. Best Practice & Research Clinical Haematology
CrossRef3
Anthony Mato, Tatyana Feldman, Joshua Richter, David S. Siegel, Andre Goy. (2012) Liquid Tumors in the Elderly. Clinics in Geriatric Medicine 28:1, 115-152
CrossRef4
Amnon Peled, Ori Wald, Jan Burger. (2012) Development of novel CXCR4-based therapeutics. Expert Opinion on Investigational Drugs1-13
CrossRef5
Markus Schaaf, Marcel Reiser, Peter Borchmann, Andreas Engert, Nicole Skoetz, Markus Schaaf. 2012. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. .
CrossRef6
Anne W Beaven, David Rizzieri. (2012) Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. Clinical Investigation 2:1, 49-58
CrossRef7
Avichai Shimoni, Irit Avivi, Jacob M. Rowe, Moshe Yeshurun, Itai Levi, Reuven Or, Paulina Patachenko, Abraham Avigdor, Tzila Zwas, Arnon Nagler. (2012) A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancern/a-n/a
CrossRef8
Marco Gunnellini, Rita Emili, Stefano Coaccioli, Anna Marina Liberati. (2012) The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma. Advances in Hematology 2012, 1-10
CrossRef9
Peter Gambell, Kirsten Herbert, Michael Dickinson, Kerrie Stokes Hons, Mathias Bressel, Dominic Wall, Simon Harrison, H. Miles Prince. (2012) Peripheral Blood CD34+ cell enumeration as a predictor of apheresis yield – an analysis of over 1000 collections. Biology of Blood and Marrow Transplantation
CrossRef10
Ajay K. Gopal, Mehdi Karami, JoAl Mayor, Mylene Macebeo, Michael Linenberger, William I. Bensinger, Leona Holmberg. (2012) The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34+ cells. Journal of Clinical Apheresisn/a-n/a
CrossRef11
Dawn Sheppard, Christopher Bredeson, David Allan, Jason Tay. (2012) Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biology of Blood and Marrow Transplantation
CrossRef12
David Telio, Kim Fernandes, Clement Ma, Richard Tsang, Armand Keating, Michael Crump, John Kuruvilla. (2011) Salvage Chemotherapy and Autologous Stem Cell Transplantation in Primary Refractory DLBCL: Outcomes and Prognostic Factors. Leukemia & Lymphoma1-19
CrossRef13
, Ji-Won Kim, Byung-Su Kim, Soo-Mee Bang, Inho Kim, Dong Hwan Kim, Won Seog Kim, Deok-Hwan Yang, Je-Jung Lee, Je-Hwan Lee, Jin Seok Kim, Sang-Kyun Sohn, Ho-Young Yhim, Jae-Yong Kwak, Sung-Soo Yoon, Jong Seok Lee, Seonyang Park, Byoung Kook Kim. (2011) Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. Annals of Hematology 90:12, 1409-1418
CrossRef14
Carlos Bachier, Josh Potter, Grant Potter, Rominna Sugay, Paul Shaughnessy, Kawah Chan, Veronica Jude, Renee Madden, Charles F. LeMaistre. (2011) High white blood cell concentration in the peripheral blood stem cell product can induce seizures during infusion of autologous peripheral blood stem cells. Biology of Blood and Marrow Transplantation
CrossRef15
J. W. Friedberg. (2011) Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematology 2011:1, 498-505
CrossRef16
Bin-Tao Huang, Qing-Chun Zeng, Jessica Yu, Zhen Xiao, Bing-Sheng Li, Chun-Lai Zhang, Hong-Bo Ji. (2011) How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. Journal of Cancer Research and Clinical Oncology
CrossRef17
Cyrus Chargari, Jean-Paul Vernant, Jerome Tamburini, Sofia Zefkili, Maryse Fayolle, Francois Campana, Alain Fourquet, Youlia M. Kirova. (2011) Feasibility of Helical Tomotherapy for Debulking Irradiation Before Stem Cell Transplantation in Malignant Lymphoma. International Journal of Radiation Oncology*Biology*Physics 81:4, 1184-1189
CrossRef18
Karin Hohloch, Carsten Oliver Sahlmann, Vijai J. Lakhani, Gerald Wulf, Bertram Glaß, Justin Hasenkamp, Johannes Meller, Joachim Riggert, Lorenz Trümper, Frank Griesinger. (2011) Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with 131I-anti-CD20 antibody and stem cell rescue. Annals of Hematology 90:11, 1307-1315
CrossRef19
Koen van Besien. (2011) Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Current Opinion in Oncology 23:6, 681-691
CrossRef20
Roni Glover, Pareen Jaideep Shenoy, Grishma A. Kharod, Allison Schaefer, Kevin Bumpers, Jamillah T. M. Berry, Christopher R. Flowers. (2011) Patterns of Social Support Among Lymphoma Patients Considering Stem Cell Transplantation. Social Work in Health Care 50:10, 815-827
CrossRef21
L. B. To, J.-P. Levesque, K. E. Herbert. (2011) How I treat patients who mobilize hematopoietic stem cells poorly. Blood 118:17, 4530-4540
CrossRef22
Keni Gu, Dennis D Weisenburger, Kai Fu, Wing C Chan, Timothy C Greiner, Patricia Aoun, Lynette M Smith, Martin Bast, Zhongfen Liu, R. Gregory Bociek, Philip J Bierman, James O Armitage, Julie M Vose. (2011) Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. Hematological Oncologyn/a-n/a
CrossRef23
Martin Hildebrandt, Dorothea Dijkstra, Hella Gollasch, Kerstin Daemen, Maja Stevanovic-Meyer, Wolf-Dieter Ludwig. (2011) Apheresis-related enrichment of CD26++ T lymphocytes: phenotypic characterization and correlation with unfavorable outcome in autologous hematopoietic progenitor cell transplantation. Transfusionno-no
CrossRef24
Nicolas Mounier, Carmen Canals, Christian Gisselbrecht, Jan Cornelissen, Roberto Foa, Eulogio Conde, John Maertens, Michel Attal, Alessandro Rambaldi, Charles Crawley, Jian-Jian Luan, Mats Brune, Sebastian Wittnebel, Gordon Cook, G.W. van Imhoff, Michael Pfreundschuh, Anna Sureda. (2011) High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry. Biology of Blood and Marrow Transplantation
CrossRef25
Esa Jantunen, Anna Sureda. (2011) The Evolving Role of Stem Cell Transplants in Lymphomas. Biology of Blood and Marrow Transplantation
CrossRef26
G. Visani, L. Malerba, P. M. Stefani, S. Capria, P. Galieni, F. Gaudio, G. Specchia, G. Meloni, F. Gherlinzoni, C. Giardini, S. Falcioni, F. Cuberli, M. Gobbi, B. Sarina, A. Santoro, F. Ferrara, M. Rocchi, E. M. Ocio, M. D. Caballero, A. Isidori. (2011) BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 118:12, 3419-3425
CrossRef27
Franca Falzetti, Mauro Di Ianni, Stelvio Ballanti, Giuseppe Iodice, Antonia Reale, Olivia Minelli, Gabriella Serio, Massimo F. Martelli, Franco Dammacco, Angelo Vacca, Roberto Ria. (2011) High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clinical and Experimental Medicine
CrossRef28
Erin T. Alexander, Jeanne A. Towery, Ashley N. Miller, Cindy Kramer, Kathy R. Hogan, Jerry E. Squires, Robert K. Stuart, Luciano J. Costa. (2011) Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming. Transfusion 51:9, 1995-2000
CrossRef29
Nishitha Reddy, Bipin N. Savani. (2011) Treatment Options for Transformed Lymphoma: Incorporating Allogeneic Stem Cell Transplantation in a Multimodality Approach. Biology of Blood and Marrow Transplantation 17:9, 1265-1272
CrossRef30
D J Andorsky, M Cohen, A Naeim, L Pinter-Brown. (2011) Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplantation 46:9, 1219-1225
CrossRef31
Michinori Ogura, Kiyoshi Ando, Masafumi Taniwaki, Takashi Watanabe, Toshiki Uchida, Ken Ohmachi, Yosuke Matsumoto, Kensei Tobinai, . (2011) Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin’s lymphoma6. Cancer Science 102:9, 1687-1692
CrossRef32
Jing Wang, Ping Zhan, Jian Ouyang, Bing Chen, Rongfu Zhou, Yonggong Yang. (2011) Standard chemotherapy is superior to high-dose chemotherapy with autologous stem cell transplantation on overall survival as the first-line therapy for patients with aggressive non-Hodgkin lymphoma: a meta-analysis. Medical Oncology 28:3, 822-828
CrossRef33
Tomohiro Aoki, Takahiro Nishiyama, Nobuhiko Imahashi, Kunio Kitamura. (2011) Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. Annals of Hematology
CrossRef34
M. Pirani, R. Marcheselli, L. Marcheselli, A. Bari, M. Federico, S. Sacchi. (2011) Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Annals of Oncology 22:8, 1845-1858
CrossRef35
Jasmine Zain, Joycelynne M. Palmer, Maria Delioukina, Sandra Thomas, Ni-Chun Tsai, Auayporn Nademanee, Leslie Popplewell, Karl Gaal, David Senitzer, Neil Kogut, Margaret O'donnell, Stephen J. Forman. (2011) Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leukemia & Lymphoma 52:8, 1463-1473
CrossRef36
Patrick J. Stiff, Ivana Micallef, Auayporn P. Nademanee, Edward A. Stadtmauer, Richard T. Maziarz, Brian J. Bolwell, Gary Bridger, Sachin Marulkar, Frank J. Hsu, John F. DiPersio. (2011) Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma. Biology of Blood and Marrow Transplantation 17:8, 1146-1153
CrossRef37
S Sinha, D Gastineau, I Micallef, W Hogan, S Ansell, F Buadi, D Dingli, A Dispenzieri, M Gertz, C Greiner, S Hayman, D Inwards, P Johnston, M Lacy, M Litzow, L Porrata, J L Winters, S Kumar. (2011) Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplantation 46:7, 943-949
CrossRef38
Gordon L. Phillips, Steven H. Bernstein, Jane L. Liesveld, Camille N. Abboud, Michael W. Becker, Louis S. Constine, J.J. Ifthikharuddin, John E. Loughner, Laurie A. Milner, David H. Vesole, Jonathan W. Friedberg. (2011) A Phase I Trial: Dose Escalation of Melphalan in the “BEAM” Regimen Using Amifostine Cytoprotection. Biology of Blood and Marrow Transplantation 17:7, 1033-1042
CrossRef39
C. Hosing, R. E. Champlin. (2011) Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. Annals of Oncology 22:7, 1471-1477
CrossRef40
Vicent M. Guillem, Cristina Arbona, Juan Carlos Hernández-Boluda, María José Terol, Rosa Goterris, Carlos Solano, Mar Tormo. (2011) An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant. Leukemia & Lymphoma 52:7, 1249-1254
CrossRef41
J Kato, T Mori, K Yokoyama, Y Tsukada, T Ueda, T Shimizu, S Okamoto. (2011) Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. Bone Marrow Transplantation 46:7, 923-928
CrossRef42
Katsuhiro Miura, Kazuhiro Takei, Sumiko Kobayashi, Satomi Kiso, Yukio Hirabayashi, Atsuko Hojo, Hitomi Kodaira, Mai Yagi, Daisuke Kurita, Yujin Kobayashi, Toshitake Tanaka, Noriyoshi Iriyama, Yoshihiro Hatta, Yoshimasa Kura, Tetsuo Yamazaki, Umihiko Sawada, Jin Takeuchi. (2011) An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma. International Journal of Hematology 94:1, 90-96
CrossRef43
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino. (2011) Diffuse large B-cell lymphoma: update on therapy and prognosis. Clinical Investigation 1:7, 989-997
CrossRef44
Amrita Krishnan, Joycelynne M. Palmer, Ni-Chun Tsai, Jennifer R. Simpson, Auayporn Nademanee, Andrew Raubitschek, Sandra H. Thomas, Stephen J. Forman. (2011) Matched-Cohort Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy versus Total Body Irradiation–Based Conditioning for Poor-Risk Diffuse Large Cell Lymphoma. Biology of Blood and Marrow Transplantation
CrossRef45
Jiří Pavlů, Holger W. Auner, Sarah Ellis, Richard M. Szydlo, Chrissy Giles, Alejandro Contento, Amin Rahemtulla, Jane F. Apperley, Kikkeri Naresh, Donald H. MacDonald, Edward J. Kanfer. (2011) LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematological Oncology 29:2, 75-80
CrossRef46
Paul Shaughnessy, Miguel Islas-Ohlmayer, Julie Murphy, Maureen Hougham, Jill MacPherson, Kurt Winkler, Matthew Silva, Michael Steinberg, Jeffrey Matous, Sheryl Selvey, Michael Maris, Peter A. McSweeney. (2011) Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide. Biology of Blood and Marrow Transplantation 17:5, 729-736
CrossRef47
Rena Buckstein, John Kuruvilla, Neil Chua, Christina Lee, David A. Macdonald, Abdulwahab J. Al-tourah, Alison H. Foo, Wendy Walsh, S. Percy ivy, Michael Crump, Elizabeth A. Eisenhauer. (2011) Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leukemia & Lymphoma 52:5, 833-841
CrossRef48
Rajni Sinha, Nutan DeJoubner, Christopher Flowers. (2011) Novel agents for diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs 20:5, 669-680
CrossRef49
Nathan Fowler, Peter McLaughlin. 2011. Non-Hodgkin Lymphomas. , 274-295.
CrossRef50
L J Costa, A N Miller, E T Alexander, K R Hogan, M Shabbir, C Schaub, R K Stuart. (2011) Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplantation 46:4, 523-528
CrossRef51
Chadi Nabhan, Nancy Davis, Jacob D. Bitran, Angel Galvez, Walter Fried, Kathy Tolzien, Susan Foss, Wendy M. Dewey, Parameswaran Venugopal. (2011) Efficacy and safety of clofarabine in relapsed and/or refractory non-hodgkin lymphoma, including rituximab-refractory patients. Cancer 117:7, 1490-1497
CrossRef52
Richard R. Furman, Michael L. Grossbard, Jeffrey L. Johnson, Andrew L. Pecora, Peter A. Cassileth, Sin-Ho Jung, Bruce A. Peterson, Lee M. Nadler, Arnold Freedman, Ruthee-Lu Bayer, Nancy L. Bartlett, David D. Hurd, Bruce D. Cheson, For The Cancer Leukemia Group B And. (2011) A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leukemia & Lymphoma 52:4, 587-596
CrossRef53
G. Illerhaus, J. Finke, A. Korfel, U. Schlegel. (2011) Therapie von primären zerebralen Lymphomen. Der Onkologe 17:4, 308-317
CrossRef54
Florian Buchkremer, Florian Buchkremer. 2011. Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity. .
CrossRef55
Brian T. Hill, Lisa Rybicki, Brian J. Bolwell, Stephen Smith, Robert Dean, Matt Kalaycio, Brad Pohlman, Shawnda Tench, Ronald Sobecks, Steven Andresen, Edward Copelan, John Sweetenham. (2011) The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. British Journal of Haematology 152:5, 561-569
CrossRef56
Celso Arrais Rodrigues, Poliana Alves Patah, Yana A. S. Novis, Chitra Hosing, Marcos Lima. (2011) The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings. Current Hematologic Malignancy Reports 6:1, 47-57
CrossRef57
Marianne B. Eide, Grete F. Lauritzsen, Gunnar Kvalheim, Arne Kolstad, Unn M. Fagerli, Martin Maisenhölder, Bjørn Østenstad, Øystein Fluge, Jan Delabie, Harald Aarset, Knut Liestøl, Harald Holte. (2011) High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. British Journal of Haematology 152:5, 600-610
CrossRef58
Partow Kebriaei, Timothy Madden, Reza Kazerooni, Xuemei Wang, Peter F. Thall, Celina Ledesma, Yago Nieto, Elizabeth J. Shpall, Chitra Hosing, Muzaffar Qazilbash, Uday Popat, Issa Khouri, Richard E. Champlin, Roy B. Jones, Borje S. Andersson. (2011) Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biology of Blood and Marrow Transplantation 17:3, 412-420
CrossRef59
Rebecca A Howman, H Miles Prince. (2011) New drug therapies in peripheral T-cell lymphoma. Expert Review of Anticancer Therapy 11:3, 457-472
CrossRef60
Daniel Harrison, Douglas E Gladstone. (2011) High-dose chemotherapy and multiple sclerosis. Current Opinion in Oncology 23:2, 221-226
CrossRef61
Ahmad S Halwani, Brian K Link. (2011) Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 11:3, 443-455
CrossRef62
D G Stover, V K Reddy, Y Shyr, B N Savani, N Reddy. (2011) Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma. Bone Marrow Transplantation
CrossRef63
C. Straka, M. Sandherr, H. Salwender, H. Wandt, B. Metzner, K. Hubel, G. Silling, M. Hentrich, D. Franke, R. Schwerdtfeger, M. Freund, O. Sezer, A. Giagounidis, G. Ehninger, W. Grimminger, A. Engert, G. Schlimok, C. Scheid, P. Hellmann, H. Heinisch, H. Einsele, A. Hinke, B. Emmerich. (2011) Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. Blood 117:7, 2121-2128
CrossRef64
Christopher J. Campen, Rebecca L. Tombleson, Myke R. Green. (2011) High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma. Journal of Neuro-Oncology 101:3, 345-355
CrossRef65
Neta Goldschmidt, Omer Or, Martine Klein, Bella Savitsky, Ora Paltiel. (2011) The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Annals of Hematology 90:2, 165-171
CrossRef66
S D Smith, B J Bolwell, L A Rybicki, T Kang, R Dean, A Advani, S Thakkar, R Sobecks, M Kalaycio, B Pohlman, J W Sweetenham. (2011) Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Bone Marrow Transplantation 46:2, 262-266
CrossRef67
Byeong-Bae Park, Won Seog Kim, Hyeon Seok Eom, Jin Seok Kim, Young Yiul Lee, Suk Joong Oh, Dae Ho Lee, Cheolwon Suh. (2011) Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin’s lymphoma: a consortium for improving survival of lymphoma (CISL) trial. Investigational New Drugs 29:1, 154-160
CrossRef68
H E Johnsen, C Geisler, E Juvonen, K Remes, G Juliusson, P Hörnsten, S Kvaloy, G Kvalheim, G W Jürgensen, L M Pedersen, O J Bergmann, A Schmitz, M Boegsted. (2011) Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment. Bone Marrow Transplantation 46:1, 44-51
CrossRef69
Yvette L. Kasamon. (2011) Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography. Advances in Hematology 2011, 1-12
CrossRef70
L J Costa, E T Alexander, K R Hogan, C Schaub, T V Fouts, R K Stuart. (2011) Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplantation 46:1, 64-69
CrossRef71
M. Pfreundschuh. (2010) How I treat elderly patients with diffuse large B-cell lymphoma. Blood 116:24, 5103-5110
CrossRef72
Carla Casulo, Steven Horwitz. (2010) Should Eligible Patients with T-Cell Lymphoma Receive High-Dose Therapy and Autologous Stem Cell Transplant in the Upfront Setting?. Current Oncology Reports 12:6, 374-382
CrossRef73
Hong-Wei Liu, Matthew D. Seftel, Morel Rubinger, David Szwajcer, Alain Demers, Zoann Nugent, Garry Schroeder, James B. Butler, Andrew Cooke. (2010) Total Body Irradiation Compared With BEAM: Long-Term Outcomes of Peripheral Blood Autologous Stem Cell Transplantation for Non-Hodgkin's Lymphoma. International Journal of Radiation Oncology*Biology*Physics 78:2, 513-520
CrossRef74
Greg Dueck, Neil Chua, Angeli Prasad, Daygen Finch, Doug Stewart, Darrell White, Richard van der Jagt, James Johnston, Andrew Belch, Tony Reiman. (2010) Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116:19, 4541-4548
CrossRef75
C Nabhan, A Ragam, J D Bitran, J Mehta. (2010) Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?. Bone Marrow Transplantation 45:9, 1379-1387
CrossRef76
J. M. Calvo-Villas, A. Martin, E. Conde, A. Pascual, I. Heras, R. Varela, J. de la Rubia, M. J. Ramirez, J. L. Diez-Martin, C. Panizo, M. J. Rodriguez-Salazar, M. J. Pascual, E. M. Donato, E. Gonzalez-Barca, M. D. Caballero, . (2010) Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. Annals of Oncology 21:9, 1891-1897
CrossRef77
Amrita Krishnan, Joycelynne M. Palmer, John A. Zaia, Ni-Chun Tsai, Joseph Alvarnas, Stephen J. Forman. (2010) HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma (NHL). Biology of Blood and Marrow Transplantation 16:9, 1302-1308
CrossRef78
M-A Perales, R Jenq, J D Goldberg, A S Wilton, S S E Lee, H R Castro-Malaspina, K Hsu, E B Papadopoulos, M R M van den Brink, F Boulad, N A Kernan, T N Small, S Wolden, N H Collins, M Chiu, G Heller, R J O'Reilly, T Kewalramani, J W Young, A A Jakubowski. (2010) Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplantation 45:9, 1408-1416
CrossRef79
Byung Woog Kang, Won Seog Kim, Chul Kim, Geundoo Jang, Sung Sook Lee, Yoon Hee Choi, Dae Ho Lee, Sang We Kim, Shin Kim, Jin-Sook Ryu, Jooryung Huh, Jung Shin Lee, Cheolwon Suh. (2010) Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Investigational New Drugs 28:4, 516-522
CrossRef80
Julie Lignon, David Sibon, Isabelle Madelaine, Pauline Brice, Patricia Franchi, Josette Briere, Nicolas Mounier, Christian Gisselbrecht, Pierre Faure, Catherine Thieblemont. (2010) Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 10:4, 262-269
CrossRef81
David Maloney, Franck Morschhauser, Ola Linden, Anton Hagenbeek, Christian Gisselbrecht. (2010) Diversity in antibody-based approaches to non-Hodgkin lymphoma. Leukemia & Lymphoma 51:S1, 20-27
CrossRef82
Kiran Manga, Geo Serban, Joseph Schwartz, Ronit Slotky, Nita Patel, Jianshe Fan, Xiaolin Bai, Ajai Chari, David Savage, Nicole Suciu-Foca, Adriana I. Colovai. (2010) Increased adenosine triphosphate production by peripheral blood CD4+ cells in patients with hematologic malignancies treated with stem cell mobilization agents. Human Immunology 71:7, 652-658
CrossRef83
Xavier Poiré, Justin Kline, David Grinblatt, Todd Zimmerman, Kathy Conner, Carolyn Muhs, Thomas Gajewski, Koen Van Besien, Sonali M. Smith. (2010) Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leukemia & Lymphoma 51:7, 1241-1250
CrossRef84
Aline Clavert, Steven Le Gouill, Eolia Brissot, Viviane Dubruille, Beatrice Mahe, Thomas Gastinne, Nicolas Blin, Patrice Chevallier, Thierry Guillaume, Jacques Delaunay, Sameh Ayari, Beatrice Saulquin, Anne Moreau, Philippe Moreau, Jean-Luc Harousseau, Noel Milpied, Mohamad Mohty. (2010) Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma 51:8, 1502-1508
CrossRef85
Jasmine M. Zain, Owen O’Connor. (2010) Targeted treatment and new agents in peripheral T-cell lymphoma. International Journal of Hematology 92:1, 33-44
CrossRef86
Rebecca L. Elstrom, Peter Martin, Katya Ostrow, Jacqueline Barrientos, Amy Chadburn, Richard Furman, Jia Ruan, Tsiporah Shore, Michael Schuster, Leandro Cerchietti, Ari Melnick, Morton Coleman, John P. Leonard. (2010) Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies. Clinical Lymphoma, Myeloma & Leukemia 10:3, 192-196
CrossRef87
Tithi Biswas, Sughosh Dhakal, Rui Chen, Ollivier Hyrien, Steven Bernstein, Jonathan W. Friedberg, Richard I. Fisher, Jane Liesveld, Gordon Phillips, Louis S. Constine. (2010) Involved Field Radiation After Autologous Stem Cell Transplant for Diffuse Large B-Cell Lymphoma in the Rituximab Era. International Journal of Radiation Oncology*Biology*Physics 77:1, 79-85
CrossRef88
H. Tilly, M. Dreyling, . (2010) Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v172-v174
CrossRef89
Yi-Bin Chen, Ephraim P. Hochberg, Yang Feng, Donna Neuberg, Bhupendra Rawal, Gabriela Motyckova, David C. Fisher, Steven L. Mcafee, Thomas R. Spitzer, Ann S. Lacasce. (2010) Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. Leukemia & Lymphoma 51:5, 789-796
CrossRef90
Mika R Kessans, Mandy L Gatesman, Denise R Kockler. (2010) Plerixafor: A Peripheral Blood Stem Cell Mobilizer. Pharmacotherapy 30:5, 485-492
CrossRef91
Arnon Nagler, Raanan Berger, Aliza Ackerstein, Jaroslaw A. Czyz, Jose Luis Diez-Martin, Elizabeth Naparstek, Reuven Or, Shlomit Gan, Avichai Shimoni, Shimon Slavin. (2010) A Randomized Controlled Multicenter Study Comparing Recombinant Interleukin 2 (rIL-2) in Conjunction With Recombinant Interferon Alpha (IFN-α) Versus no Immunotherapy for Patients With Malignant Lymphoma Postautologous Stem Cell Transplantation. Journal of Immunotherapy 33:3, 326-333
CrossRef92
David C. Linch, Lynny Yung, Paul Smith, Ken Maclennan, Andrew Jack, Barry Hancock, David Cunningham, Peter Hoskin, Wendi Qian, Harald Holte, Anne-Marie Boesen, Andrew Grigg, Peter Browett, Marek Trneny. (2010) Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. British Journal of Haematology 149:2, 237-243
CrossRef93
Michael Dickinson, Rosemary Hoyt, Andrew W. Roberts, Andrew Grigg, John F. Seymour, H. Miles Prince, Jeff Szer, David Ritchie. (2010) Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. British Journal of Haematologyno-no
CrossRef94
Patrick Wuchter, Dan Ran, Thomas Bruckner, Thomas Schmitt, Mathias Witzens-Harig, Kai Neben, Hartmut Goldschmidt, Anthony D. Ho. (2010) Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation. Biology of Blood and Marrow Transplantation 16:4, 490-499
CrossRef95
Carsten Zwick, Niels Murawski, Michael Pfreundschuh. (2010) Rituximab in High-Grade Lymphoma. Seminars in Hematology 47:2, 148-155
CrossRef96
Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, William J. Hogan, Svetomir N. Markovic. (2010) New-Onset Lymphopenia Assessed during Routine Follow-up Is a Risk Factor for Relapse Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma. Biology of Blood and Marrow Transplantation 16:3, 376-383
CrossRef97
Paolo F. Caimi, Paul M. Barr, Nathan A. Berger, Hillard M. Lazarus. (2010) Non-Hodgkinʼs Lymphoma in the Elderly. Drugs & Aging 27:3, 211-238
CrossRef98
Niels Murawski, Carsten Zwick, Michael Pfreundschuh. (2010) Unresolved issues in diffuse large B-cell lymphomas. Expert Review of Anticancer Therapy 10:3, 387-402
CrossRef99
Andrea Borgerding, Justin Hasenkamp, Bertram Glaß, Gerald Wulf, Lorenz Trümper. (2010) Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Annals of Hematology 89:3, 283-289
CrossRef100
Panagiotis Tsirigotis, Liliane Dray, Igor B. Resnick, Aliza Ackerstein, Benjamin Gesundheit, Sharon Elad, Reuven Or, Michael-Yechiel Shapira. (2010) Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin’s lymphoma. Annals of Hematology 89:3, 263-272
CrossRef101
M R Litzow, P P Peethambaram, S L Safgren, G L Keeney, S M Ansell, A Dispenzieri, M A Elliott, D A Gastineau, M A Gertz, D J Inwards, M Q Lacy, I N M Micallef, L F Porrata, W L Lingle, L C Hartmann, M H Frost, B A Barrette, H J Long, V J Suman, J M Reid, M M Ames, S H Kaufmann. (2010) Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplantation 45:3, 490-497
CrossRef102
A Numata, T Miyamoto, Y Ohno, T Kamimura, K Kamezaki, T Tanimoto, K Takase, H Henzan, K Kato, K Takenaka, T Fukuda, N Harada, K Nagafuji, T Teshima, K Akashi, M Harada, T Eto. (2010) Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplantation 45:2, 311-316
CrossRef103
J E Benjamin, G L Chen, T M Cao, P D Cao, R M Wong, K Sheehan, J A Shizuru, L J Johnston, R S Negrin, R Lowsky, G G Laport. (2010) Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Bone Marrow Transplantation 45:2, 303-309
CrossRef104
P Ljungman, M Bregni, M Brune, J Cornelissen, T de Witte, G Dini, H Einsele, H B Gaspar, A Gratwohl, J Passweg, C Peters, V Rocha, R Saccardi, H Schouten, A Sureda, A Tichelli, A Velardi, D Niederwieser. (2010) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplantation 45:2, 219-234
CrossRef105
Wenli Qiao, Jinhua Zhao, Chun Wang, Taisong Wang, Yan Xing. (2010) Predictive value of <SUP>18</SUP>F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Hematology 15:1, 21-27
CrossRef106
Maria Teresa Bortolin, Stefania Zanussi, Renato Talamini, Cecilia Simonelli, Chiara Pratesi, Rosamaria Tedeschi, Luciano Abbruzzese, Rosa Manuele, Maurizio Rupolo, Umberto Tirelli, Paolo De Paoli. (2010) Predictive Value of HIV Type 1 DNA Levels on Overall Survival in HIV-Related Lymphoma Patients Treated with High-Dose Chemotherapy (HDC) Plus Autologous Stem Cell Transplantation (ASCT). AIDS Research and Human Retroviruses 26:2, 245-251
CrossRef107
Anne Sirvent, Nathalie Dhedin, Mauricette Michallet, Nicolas Mounier, Catherine Faucher, Ibrahim Yakoub-Agha, Mohamad Mohty, Marie Robin, Reza Tabrizi, Laurence Clement, Karin Bilger, Fabrice Larosa, Nathalie Contentin, Anne Huyn, Sylvie François, Claude-Eric Bulabois, Patrice Ceballos, Jean-Henri Bourrhis, Agnès Buzyn, Jérôme Cornillon, Gaelle Guillerm, Thierry de Revel, Jacques-Olivier Bay, François Guilhot, Noël Milpied. (2010) Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B Cell Lymphoma: Report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Biology of Blood and Marrow Transplantation 16:1, 78-85
CrossRef108
Robert M. Dean, Brad Pohlman, John W. Sweetenham, Ronald M. Sobecks, Matt E. Kalaycio, Stephen D. Smith, Edward A. Copelan, Steven Andresen, Lisa A. Rybicki, Julie Curtis, Brian J. Bolwell. (2010) Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. British Journal of Haematology 148:2, 226-234
CrossRef109
Sushrut Patil, Andrew Spencer, Anthony Schwarer, Sharon Avery, David Ritchie, Stephen Opat, Andrew Wei, Catriona Mclean. (2009) Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leukemia & Lymphoma 50:12, 1964-1968
CrossRef110
Tamara Intermesoli, Jonathan Shamash, Ama Rohatiner, Andrew Wilson, Andrew Lister, Silvia Montoto. (2009) Low dose continuous chemotherapy (LD56): an active treatment with low toxicity for patients with recurrent/refractory lymphoma not eligible for intensive salvage therapy. British Journal of Haematology 147:3, 408-410
CrossRef111
Matthew Ulrickson, Julie Aldridge, Haesook T. Kim, Ephraim P. Hochberg, Peter Hammerman, Christine Dube, Eyal Attar, Karen K. Ballen, Bimalangshu R. Dey, Steven L. McAfee, Thomas R. Spitzer, Yi-Bin Chen. (2009) Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience. Biology of Blood and Marrow Transplantation 15:11, 1447-1454
CrossRef112
Timothy S. Fenske, Parameswaran N. Hari, Jeanette Carreras, Mei-Jie Zhang, Rammurti T. Kamble, Brian J. Bolwell, Mitchell S. Cairo, Richard E. Champlin, Yi-Bin Chen, César O. Freytes, Robert Peter Gale, Gregory A. Hale, Osman Ilhan, H. Jean Khoury, John Lister, Dipnarine Maharaj, David I. Marks, Reinhold Munker, Andrew L. Pecora, Philip A. Rowlings, Thomas C. Shea, Patrick Stiff, Peter H. Wiernik, Jane N. Winter, J. Douglas Rizzo, Koen van Besien, Hillard M. Lazarus, Julie M. Vose. (2009) Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation 15:11, 1455-1464
CrossRef113
Yan Song, Zhi Cao, Qin Su, Ling Li, Hongtu Zhang, Yuankai Shi, Xun Zhang. (2009) Expression profile of CD10, Bcl-6, CD138, Bcl-2 and MUM1 and their prognostic value in 136 patients with diffuse large B-cell lymphoma. The Chinese-German Journal of Clinical Oncology 8:10, 585-591
CrossRef114
Navneet S. Majhail, Ruta Bajorunaite, Hillard M. Lazarus, Zhiwei Wang, John P. Klein, Mei-Jie Zhang, J. Douglas Rizzo. (2009) Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. British Journal of Haematology 147:1, 129-139
CrossRef115
Francesco d’Amore, Esa Jantunen, Thomas Relander. (2009) Hemopoietic stem cell transplantation in T-cell malignancies: Who, when, and how?. Current Hematologic Malignancy Reports 4:4, 236-244
CrossRef116
C. Zwick, N. Murawski, Michael Pfreundschuh. (2009) Treatment of diffuse large B-cell lymphomas. memo - Magazine of European Medical Oncology 2:3, 150-153
CrossRef117
J. Rodríguez, A. Gutiérrez, B. Martínez-Delgado, G. Perez-Manga. (2009) Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Critical Reviews in Oncology/Hematology 71:3, 181-198
CrossRef118
Catherine Thieblemont, Christian Gisselbrecht. (2009) Second-line treatment paradigms for diffuse large B-cell lymphomas. Current Oncology Reports 11:5, 386-393
CrossRef119
N M Brown, S Y Kim, P A Ford. (2009) Autologous stem cell transplants in Jehovah's Witnesses. Bone Marrow Transplantation 44:6, 391-392
CrossRef120
Shen Yang, Yao Yu, Li Jun-Min, Mi Jian-Qing, Chen Qiu-Sheng, Chen Yu, Zhao Wei-Li, You Jian-Hua, Zhao Hui-Jin, Wang Yan, Wang Li, Cheng Shu, Shen Zhi-Xiang. (2009) Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population. Annals of Hematology 88:9, 863-869
CrossRef121
A. Re, M. Michieli, S. Casari, B. Allione, C. Cattaneo, M. Rupolo, M. Spina, R. Manuele, E. Vaccher, M. Mazzucato, L. Abbruzzese, P. Ferremi, G. Carosi, U. Tirelli, G. Rossi. (2009) High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 114:7, 1306-1313
CrossRef122
J. Prajogo, A. Neil, J. Duke, H. Zhang, B. Stokes, P. Rowlings. (2009) Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting. Internal Medicine Journal 39:8, 519-526
CrossRef123
Paul M. Barr, Hillard M. Lazarus, Brenda W. Cooper, Mark D. Schluchter, Ashok Panneerselvam, James W. Jacobberger, Jack W. Hsu, Nalini Janakiraman, Aleksandra Simic, Afshin Dowlati, Scot C. Remick. (2009) Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. American Journal of Hematology 84:8, 484-487
CrossRef124
M Heizmann, A C O'Meara, P R Moosmann, I A F M Heijnen, M Zuberbühler, P Fernandez, J Burger, A Huber, M Wernli, M J Bargetzi. (2009) Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma. Bone Marrow Transplantation 44:2, 75-79
CrossRef125
P G Gobbi, F Valentino, P Lambelet, V Perfetti, G Bergamaschi, M Girino, G R Corazza. (2009) Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs. Bone Marrow Transplantation 44:1, 19-25
CrossRef126
M P Escalón, A Stefanovic, A Venkatraman, D Pereira, E S Santos, M Goodman, J J Byrnes, H F Fernandez. (2009) Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplantation 44:2, 89-96
CrossRef127
H.G. Sayer, D.W. Beelen. (2009) Hämatopoetische Stammzelltransplantation. Der Onkologe 15:6, 564-574
CrossRef128
Sun Jin Sym, Dae Ho Lee, Hye Jin Kang, Seung Hyun Nam, Ho Young Kim, Seok Jin Kim, Hyeon Seok Eom, Won Seog Kim, Cheolwon Suh. (2009) A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma. Cancer Chemotherapy and Pharmacology 64:1, 27-33
CrossRef129
B S Hoppe, C H Moskowitz, Z Zhang, J C Maragulia, R D Rice, A S Reiner, P A Hamlin, A D Zelenetz, J Yahalom. (2009) The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation 43:12, 941-948
CrossRef130
Chitra Hosing, Rima M. Saliba, Sheena Ahlawat, Martin Körbling, Partow Kebriaei, Amin Alousi, Marcos De Lima, Julia-Grace Okoroji, John McMannis, Muzaffar Qazilbash, Paolo Anderlini, Sergio Giralt, Richard E. Champlin, Issa Khouri, Uday Popat. (2009) Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. American Journal of Hematology 84:6, 335-337
CrossRef131
Yutaka Shimazu, Kenji Notohara, Yasunori Ueda. (2009) Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. International Journal of Hematology 89:5, 577-583
CrossRef132
Mehdi Hamadani, Don M. Benson, Craig C. Hofmeister, Patrick Elder, William Blum, Pierluigi Porcu, Ramiro Garzon, Kristie A. Blum, Thomas S. Lin, Guido Marcucci, Steven M. Devine. (2009) Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation 15:5, 547-553
CrossRef133
H. Tilly, M. Dreyling, . (2009) Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv110-iv112
CrossRef134
Antonello Malfitano, Giuseppe Barbaro, Giorgio Barbarini. (2009) Ongoing change in the treatment of HIV-associated malignancies in the HAART era. Expert Review of Clinical Pharmacology 2:3, 283-293
CrossRef135
Xavier Poiré, Koen van Besien. (2009) Autologous transplant for primary mediastinal B-cell lymphoma. Expert Review of Hematology 2:1, 31-36
CrossRef136
J Ho, L Yang, B Banihashemi, L Martin, M Halpenny, H Atkins, M Sabloff, S A McDiarmid, L B Huebsch, I Bence-Bruckler, A Giulivi, D S Allan. (2009) Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone Marrow Transplantation 43:3, 223-228
CrossRef137
W Bensinger, J F DiPersio, J M McCarty. (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplantation 43:3, 181-195
CrossRef138
Philippe Fagnoni, Noel Milpied, Samuel Limat, Eric Deconinck, Virginie Nerich, Charles Foussard, Philippe Colombat, Jean-Luc Harousseau, Marie-Christine Woronoff-Lemsi. (2009) Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkinʼs Lymphoma. PharmacoEconomics 27:1, 55-68
CrossRef139
Sung Jin Hong, Jin Seok Kim, Jong Hee Chang, Kyoung Min Kim, Soo Jeong Kim, Hye Won Lee, June-Won Cheong, Seung Tae Lee, Yoo Hong Min. (2009) A Successful Treatment of Relapsed Primary CNS Lymphoma Patient with Intraventricular Rituximab Followed by High-Dose Chemotherapy with Autologous Stem Cell Rescue. Yonsei Medical Journal 50:2, 280
CrossRef140
Tomer Mark, Peter Martin, John P Leonard, Ruben Niesvizky. (2009) Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opinion on Investigational Drugs 18:1, 99-104
CrossRef141
Deok-Hwan Yang, Won Seog Kim, Seok Jin Kim, Sung Hwa Bae, Sung Hyun Kim, In Ho Kim, Sung Soo Yoon, Yeung-Chul Mun, Ho-Jin Shin, Yee Soo Chae, Jae-Yong Kwak, Hawk Kim, Min Kyoung Kim, Jin Seok Kim, Jong Ho Won, Je-Jung Lee, Cheol Won Suh. (2009) Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome. Biology of Blood and Marrow Transplantation 15:1, 118-125
CrossRef142
Thomas C. Shea, Anne W. Beaven, Dominic T. Moore, Jonathan S. Serody, Don A. Gabriel, Nelson Chao, Jon P. Gockerman, Reynaldo A. Garcia, David A. Rizzieri. (2009) Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leukemia & Lymphoma 50:5, 741-748
CrossRef143
R Z Yusuf, B Dey, B Y Yeap, S McAfee, E Attar, P S Sepe, C Dube, T R Spitzer, K K Ballen. (2009) Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation 43:1, 37-42
CrossRef144
Yi Niu, Yuankai Shi, Shengyu Zhou, Feng Pan, Shikai Wu, Peng Liu, Jiangliang Yang, Xiaohong Han, Xiaohui He. (2009) Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma. International Journal of Hematology 89:1, 106-112
CrossRef145
Kaori IDE, Yuko GOTO-KOSHINO, Yasuyuki MOMOI, Yasuhito FUJINO, Koichi OHNO, Hajime TSUJIMOTO. (2009) Quantitative Analysis of mRNA Transcripts of Hox, SHH, PTCH, Wnt, and Fzd Genes in Canine Hematopoietic Progenitor Cells and Various in vitro Colonies Differentiated from the Cells. Journal of Veterinary Medical Science 71:1, 69-77
CrossRef146
Tara Seshadri, Armand Keating. (2009) Is There a Role for Autotransplants in AML in First Remission?. Biology of Blood and Marrow Transplantation 15:1, 17-20
CrossRef147
Amrita Krishnan. (2009) HIV-Infected Patients. Biology of Blood and Marrow Transplantation 15:1, 142-145
CrossRef148
Amrita Krishnan. (2009) Stem cell transplantation in HIV-infected patients. Current Opinion in HIV and AIDS 4:1, 11-15
CrossRef149
Hillard M. Lazarus, Jeanette Carreras, Christian Boudreau, Fausto R. Loberiza, James O. Armitage, Brian J. Bolwell, César O. Freytes, Robert Peter Gale, John Gibson, Gregory A. Hale, David J. Inwards, Charles F. LeMaistre, Dipnarine Maharaj, David I. Marks, Alan M. Miller, Santiago Pavlovsky, Harry C. Schouten, Koen van Besien, Julie M. Vose, Jacob D. Bitran, Issa F. Khouri, Philip L. McCarthy, Hongmei Yu, Philip Rowlings, Derek S. Serna, Mary M. Horowitz, J. Douglas Rizzo. (2008) Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR). Biology of Blood and Marrow Transplantation 14:12, 1323-1333
CrossRef150
Sant-Rayn Pasricha, Andrew Grigg, John Catalano, Michael Leahy, Craig Underhill, Chris Arthur, James D'Rozario, Ray Lowenthal, Kate Reed, Andrew Spencer. (2008) A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer 113:11, 3192-3198
CrossRef151
G. Hess. (2008) Radioimmunotherapy – still experimental? Rational, proven indications and future trends. memo - Magazine of European Medical Oncology 1:4, 193-203
CrossRef152
Mehdi Hamadani, Don M. Benson Jr., Thomas S. Lin, Pierluigi Porcu, Kristie A. Blum, Steven M. Devine. (2008) High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. European Journal of Haematology 81:6, 425-431
CrossRef153
Andrew R. Rezvani, Lalitha Norasetthada, Ted Gooley, Mohamed Sorror, Michelle E. Bouvier, Firoozeh Sahebi, Edward Agura, Thomas Chauncey, Richard T. Maziarz, Michael Maris, Judith Shizuru, Benedetto Bruno, Christopher Bredeson, Thoralf Lange, Andrew Yeager, Brenda M. Sandmaier, Rainer F. Storb, David G. Maloney. (2008) Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. British Journal of Haematology 143:3, 395-403
CrossRef154
Enrico Derenzini, Gerardo Musuraca, Stefano Fanti, Vittorio Stefoni, Monica Tani, Lapo Alinari, Filippo Venturini, Letizia Gandolfi, Michele Baccarani, Pier Luigi Zinzani. (2008) Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 113:9, 2496-2503
CrossRef155
Timothy S Fenske, Heather Benjamin, Steven H Kroft, Eric J Hohenwalter, William S Rilling. (2008) Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization. Nature Clinical Practice Oncology 5:11, 677-681
CrossRef156
L Damon, L E Damon, K Gaensler, L Kaplan, T Martin, J Rubenstein, C Linker. (2008) Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplantation 42:10, 649-657
CrossRef157
David Wrench, John G. Gribben. (2008) Stem Cell Transplantation for Non-Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America 22:5, 1051-1079
CrossRef158
Luciano J. Costa, Ivana N. Micallef, David J. Inwards, Patrick B. Johnston, Luis F. Porrata, Mark R. Litzow, Stephen M. Ansell. (2008) Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. British Journal of Haematology 143:2, 268-273
CrossRef159
T. Seshadri, J. Stakiw, M. Pintilie, A. Keating, M. Crump, J. Kuruvilla. (2008) Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy. Hematology 13:5, 261-266
CrossRef160
Jonathan W. Friedberg, Richard I. Fisher. (2008) Diffuse Large B-Cell Lymphoma. Hematology/Oncology Clinics of North America 22:5, 941-952
CrossRef161
P W M Johnson. (2008) Survival from non-Hodgkin lymphoma in England and Wales up to 2001. British Journal of Cancer 99, S107-S109
CrossRef162
Maricer P Escalón, Izidore S Lossos. (2008) Pharmacotherapy of large B-cell lymphoma. Expert Opinion on Pharmacotherapy 9:13, 2247-2258
CrossRef163
Carsten Zwick, Josef Birkmann, Norma Peter, Heinrich Bodenstein, Roland Fuchs, Mathias Hänel, Marcel Reiser, Manfred Hensel, Michael Clemens, Samira Zeynalova, Marita Ziepert, Michael Pfreundschuh. (2008) Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). Annals of Hematology 87:9, 717-726
CrossRef164
Iskra Pusic, Shi Yuan Jiang, Scott Landua, Geoffrey L. Uy, Michael P. Rettig, Amanda F. Cashen, Peter Westervelt, Ravi Vij, Camille N. Abboud, Keith E. Stockerl-Goldstein, Diane S. Sempek, Angela L. Smith, John F. DiPersio. (2008) Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. Biology of Blood and Marrow Transplantation 14:9, 1045-1056
CrossRef165
Amin M. Alousi, Rima M. Saliba, Grace-Julia Okoroji, Homer A. Macapinlac, Chitra Hosing, Martin Korbling, Barry I. Samuels, Uday Popat, Partow Kebriaei, Paolo Anderlini, Muzaffar H. Qazilbash, Marcos de Lima, Sergio A. Giralt, Richard E. Champlin, Issa F. Khouri. (2008) Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. British Journal of Haematology 142:5, 786-792
CrossRef166
Vaishalee Padgaonkar Kenkre, Sonali M. Smith. (2008) Management of relapsed diffuse large B-cell lymphoma. Current Oncology Reports 10:5, 393-403
CrossRef167
Luciano Wannesson, Emanuele Zucca. (2008) Who should receive myeloablative therapy for diffuse large B-cell lymphoma?. Nature Clinical Practice Oncology 5:8, 442-443
CrossRef168
Luciano J. Costa, Andrew L. Feldman, Ivana N. Micallef, David J. Inwards, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell. (2008) Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. British Journal of Haematology 142:3, 404-412
CrossRef169
Sonali M. Smith, Koen van Besien, Jeanette Carreras, Asad Bashey, Mitchell S. Cairo, Cesar O. Freytes, Robert Peter Gale, Gregory A. Hale, Brandon Hayes-Lattin, Leona A. Holmberg, Armand Keating, Richard T. Maziarz, Philip L. McCarthy, Willis H. Navarro, Santiago Pavlovsky, Harry C. Schouten, Matthew Seftel, Peter H. Wiernik, Julie M. Vose, Hillard M. Lazarus, Parameswaran Hari. (2008) Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. Biology of Blood and Marrow Transplantation 14:8, 904-912
CrossRef170
Lale Kostakoglu. (2008) Early prediction of response to therapy: the clinical implications in Hodgkin’s and non-Hodgkin’s lymphoma. European Journal of Nuclear Medicine and Molecular Imaging 35:8, 1413-1420
CrossRef171
Hye Jin Kang, Won Seog Kim, Cheolwon Suh, Yeon Hee Park, Bong Seog Kim, Young Jin Yuh, Baek-Yeol Ryoo. (2008) Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. Cancer Chemotherapy and Pharmacology 62:2, 299-304
CrossRef172
John Kuruvilla, Gregory Pond, Richard Tsang, Vikas Gupta, Jeffrey H. Lipton, Hans A. Messner. (2008) Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma. Biology of Blood and Marrow Transplantation 14:7, 775-782
CrossRef173
M. R. Bishop, R. M. Dean, S. M. Steinberg, J. Odom, S. Z. Pavletic, C. Chow, S. Pittaluga, C. Sportes, N. M. Hardy, J. Gea-Banacloche, A. Kolstad, R. E. Gress, D. H. Fowler. (2008) Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Annals of Oncology 19:11, 1935-1940
CrossRef174
Shireen Kassam, Silvia Montoto. (2008) Oncologic, Endocrine & Metabolic Emerging drugs in B-cell non-Hodgkin's lymphoma. Expert Opinion on Emerging Drugs 13:2, 323-343
CrossRef175
Christoph Oehler-Jänne, Christian Taverna, Nadine Stanek, Laura Negretti, Urs M. Lütolf, Ilja F. Ciernik. (2008) Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study. Hematological Oncology 26:2, 82-90
CrossRef176
Marcie Tomblyn, Claudio Brunstein, Linda J. Burns, Jeffrey S. Miller, Margaret MacMillan, Todd E. DeFor, Daniel J. Weisdorf. (2008) Similar and Promising Outcomes in Lymphoma Patients Treated with Myeloablative or Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 14:5, 538-545
CrossRef177
Ignacio G. Escobar, Pilar T. Alonso, Dolores C. Barrigon, Jose A. Perez-Simon, Maria V. Mateos Manteca, Jesus F. San Miguel Izquierdo. (2008) Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation. Annals of Nuclear Medicine 22:4, 251-260
CrossRef178
Peng-Chan Lin, Ming-Yang Lee, Jen-Tsun Lin, Liang-Tsai Hsiao, Po-Min Chen, Tzeon-Jye Chiou. (2008) Virus reactivation in high-risk non-Hodgkin’s lymphoma patients after autologous CD34+-selected peripheral blood progenitor cell transplantation. International Journal of Hematology 87:4, 434-439
CrossRef179
Ming-Yang Lee, Tzeon-Jye Chiou, Liang-Tsai Hsiao, Muh-Hwa Yang, Pang-Chan Lin, Say-Bee Poh, Chueh-Chuan Yen, Jin-Hwang Liu, Hao-Wei Teng, Ta-Chung Chao, Wei-Shu Wang, Po-Min Chen. (2008) Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation. Annals of Hematology 87:4, 285-289
CrossRef180
J. Szer. (2008) Harvesting haemopoietic stem cells for future use: rainy days, real or imagined?. Internal Medicine Journal 38:4, 227-228
CrossRef181
Timo Kapp, Krueger Magnus, Ott Ingo, Steiner Stefanie, Schumacher Petra, Nachbaur David, Gastl Günther, Gust Ronald, Brigitte Kircher. (2008) Biological effect of mono- and dinuclear alkylamine platinum(II) compounds on human lymphoma cells. Journal of Inorganic Biochemistry 102:4, 713-720
CrossRef182
L J Costa, I N Micallef, D J Inwards, P B Johnston, L F Porrata, S M Ansell. (2008) Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplantation 41:8, 715-720
CrossRef183
Michelle M. Zhang, Ajay K. Gopal. (2008) Radioimmunotherapy-Based Conditioning Regimens for Stem Cell Transplantation. Seminars in Hematology 45:2, 118-125
CrossRef184
Tara Seshadri, John Kuruvilla, Michael Crump, Armand Keating. (2008) Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation 14:3, 259-267
CrossRef185
P. Fu, W.J. van Heeckeren, P.D. Wadhwa, D.J. Bajor, R.J. Creger, Z. Xu, B.W. Cooper, M.J. Laughlin, S.L. Gerson, O.N. Koç, H.M. Lazarus. (2008) Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation. Contemporary Clinical Trials 29:2, 157-164
CrossRef186
Nina D Wagner-Johnston, Richard F Ambinder. (2008) Blood and marrow transplant for lymphoma patients with HIV/AIDS. Current Opinion in Oncology 20:2, 201-205
CrossRef187
J Kline, S Subbiah, H M Lazarus, K van Besien. (2008) Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplantation 41:6, 505-513
CrossRef188
A Shimoni, S T Zwas, Y Oksman, I Hardan, N Shem-Tov, A Rand, R Yerushalmi, A Avigdor, I Ben-Bassat, A Nagler. (2008) Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplantation 41:4, 355-361
CrossRef189
Susana Vives, Juan-Manuel Sancho, Jordi Juncà, Joan-Ramon Grifols, Mireia Morgades, Josep-Maria Ribera. (2008) Tratamiento de rescate y movilización de progenitores hematopoyéticos de sangre periférica con altas dosis de ifosfamida y etopósido en pacientes con linfoma. Medicina Clínica 130:5, 172-174
CrossRef190
Andrés López, Antonio Gutiérrez, Andrés Palacios, Isabel Blancas, Maite Navarrete, Miguel Morey, Antonia Perelló, Jesús Alarcón, Jordi Martínez, José Rodríguez. (2008) GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. European Journal of Haematology 80:2, 127-132
CrossRef191
Alexander Greb, Julia Bohlius, Daniel Schiefer, Guido Schwarzer, Holger Schulz, Andreas Engert, Alexander Greb. 2008. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. .
CrossRef192
Florian Buchkremer, Florian Buchkremer. 2008. Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity. .
CrossRef193
J. A. Thompson, R. I. Fisher, M. LeBlanc, S. J. Forman, O. W. Press, J. M. Unger, A. P. Nademanee, P. J. Stiff, S. H. Petersdorf, A. Fefer. (2008) Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 111:8, 4048-4054
CrossRef194
Renata Zaucha, Ted Gooley, Leona Holmberg, Ajay K. Gopal, Oliver Press, David Maloney, William I. Bensinger. (2008) High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leukemia & Lymphoma 49:10, 1899-1906
CrossRef195
Jae-Cheol Jo, Byung Wook Kang, Geundoo Jang, Sun Jin Sym, Sung Sook Lee, Ja Eun Koo, Jong Wook Kim, Shin Kim, Jooryung Huh, Cheolwon Suh. (2008) BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Annals of Hematology 87:1, 43-48
CrossRef196
Lale Kostakoglu. (2008) FDG-PET Evaluation of Response to Treatment. PET Clinics 3:1, 37-75
CrossRef197
John Kuruvilla, Melania Pintilie, Richard Tsang, Tracy Nagy, Armand Keating, Michael Crump. (2008) Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leukemia & Lymphoma 49:7, 1329-1336
CrossRef198
Mariano Provencio, Luis E. Fayad. (2008) Quimioterapia intensiva y de rescate con progenitores hematopoyéticos autólogos en el tratamiento de los linfomas no hodgkinianos. Medicina Clínica 130:2, 60-65
CrossRef199
Alessandro Pavan, Michele Spina, Vincenzo Canzonieri, Silvia Sansonno, Giuseppe Toffoli, Valli De Re. (2008) Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-κB pathway as a target for new therapeutic strategies. Leukemia & Lymphoma 49:11, 2048-2058
CrossRef200
Thomas R. Spitzer, Richard F. Ambinder, Jeannette Y. Lee, Lawrence D. Kaplan, William Wachsman, David J. Straus, David M. Aboulafia, David T. Scadden. (2008) Dose-Reduced Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation for Human Immunodeficiency Virus–Associated Lymphoma: AIDS Malignancy Consortium Study 020. Biology of Blood and Marrow Transplantation 14:1, 59-66
CrossRef201
Thomas E. Witzig, Susan M. Geyer, Paul J. Kurtin, Joseph P. Colgan, David J. Inwards, Ivana N. M. Micallef, Betsy R. LaPlant, John C. Michalak, Muhammad Salim, Robert J. Dalton, Dennis F. Moore, Craig B. Reeder. (2008) Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group. Leukemia & Lymphoma 49:6, 1074-1080
CrossRef202
Kaori IDE, Shinobu MATSUURA, Yasuhito FUJINO, Koichi OHNO, Hajime TSUJIMOTO. (2008) Investigation of Various Methods for the Cryopreservation of Canine Bone Marrow-Derived CD34+ Cells. Journal of Veterinary Medical Science 70:11, 1211-1217
CrossRef203
Roberto Crocchiolo, Carla Canevari, Andrea Assanelli, Francesca Lunghi, Michela Tassara, Maria Lupo Stanghellini, Daniela Clerici, Claudio Landoni, Paolo Servida, Massimo Bernardi, Jacopo Peccatori, Andres Ferreri, Luigi Gianolli, Claudio Bordignon, Federico Caligaris-Cappio, Fabio Ciceri, Ferruccio Fazio. (2008) Pre-transplant 18 FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leukemia & Lymphoma 49:4, 727-733
CrossRef204
Ock Bae Ko, Geundoo Jang, Shin Kim, Jooryung Huh, Cheolwon Suh. (2008) Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement. The Korean journal of internal medicine 23:4, 182
CrossRef205
Helge Menzel, Andrea Müller, Christoph Von Schilling, Thomas Licht, Christian Peschel, Ulrich Keller. (2008) Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: Analysis of remission induction and stem cell mobilization. Leukemia & Lymphoma 49:7, 1337-1344
CrossRef206
Mehdi Hamadani, Farrukh T. Awan, Patrick Elder, Thomas S. Lin, Pierluigi Porcu, Don M. Benson, Kristie A. Blum, Steven M. Devine. (2008) Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leukemia & Lymphoma 49:10, 1893-1898
CrossRef207
Peter Mclaughlin, Julie M. Vose. (2008) R-DHAP: A good small step, but not the journey's end. Leukemia & Lymphoma 49:6, 1019-1021
CrossRef208
Scott Rowley, Thea M. Friedman, Robert Korngold. 2008. Hematopoietic stem cell transplantation for malignant diseases. , 1223-1236.
CrossRef209
C Gisselbrecht, W Bethge, R F Duarte, A M Gianni, B Glass, C Haioun, G Martinelli, A Nagler, R Pettengell, A Sureda, H Tilly, K Wilson. (2007) Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation 40:11, 1007-1017
CrossRef210
R N Pham, T A Gooley, G E Keeney, O W Press, J M Pagel, H A Greisman, W I Bensinger, L A Holmberg, S H Petersdorf, D G Maloney, A K Gopal. (2007) The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. Bone Marrow Transplantation 40:11, 1039-1044
CrossRef211
Qingyuan Zhang, Jingxuan Wang, Jincai Wang. (2007) Biweekly CHOP therapy improves therapeutic effect in the non-GCB subtype of diffuse large B-cell lymphoma. Central European Journal of Medicine 2:4, 488-498
CrossRef212
Simon Fluri, Roland Ammann, Annette Ridolfi Lüthy, Andreas Hirt, Christoph Aebi, Andrea Duppenthaler, Kurt Leibundgut. (2007) High-dose therapy and autologous stem cell transplantation for children with HIV-associated non-Hodgkin lymphoma. Pediatric Blood & Cancer 49:7, 984-987
CrossRef213
J G Kim, S K Sohn, Y S Chae, D H Yang, J-J Lee, H-J Kim, H J Shin, J S Jung, W S Kim, D H Kim, C Suh, S J Kim, H-S Eom, S H Bae. (2007) Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation 40:10, 919-924
CrossRef214
Pier F. Ferrucci, Anna Vanazzi, Chiara M. Grana, Marta Cremonesi, Mirco Bartolomei, Marco Chinol, Mahila Ferrari, Davide Radice, Stefano Papi, Giovanni Martinelli, Giovanni Paganelli. (2007) High activity 90 Y-ibritumomab tiuxetan (Zevalin ® ) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. British Journal of Haematology 139:4, 590-599
CrossRef215
Yutaka Tokuda, Tomoo Tajima, Masaru Narabayashi, Kunihiko Takeyama, Toru Watanabe, Takashi Fukutomi, Takaaki Chou, Muneaki Sano, Tadahiko Igarashi, Yasutsuna Sasaki, Michinori Ogura, Shigeto Miura, Shin-ichiro Okamoto, Masami Ogita, Masaharu Kasai, Tadashi Kobayashi, Haruhiko Fukuda, Shigemitsu Takashima, Kensei Tobinai, , . (2007) Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Science 0:0, 071027181834001-???
CrossRef216
John G. Gribben. 2007. Management of Haematological Malignancies. .
CrossRef217
Shunji Takahashi, Keisuke Aiba, Yoshinori Ito, Kiyohiko Hatake, Minoru Nakane, Takayuki Kobayashi, Sayuri Minowa, Harumi Shibata, Junko Mitsuhashi, Satomi Tsukahara, Etsuko Ishikawa, Rieko Suzuki, Takashi Tsuruo, Yoshikazu Sugimoto. (2007) Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients. Cancer Science 98:10, 1609-1616
CrossRef218
Norbert Schmitz, Christian Buske, Christian Gisselbrecht. (2007) Autologous Stem Cell Transplantation in Lymphoma. Seminars in Hematology 44:4, 234-245
CrossRef219
Junko Mitsuhashi, Satomi Tsukahara, Rieko Suzuki, Yumiko Oh-Hara, Saori Nishi, Hiroyo Hosoyama, Kazuhiro Katayama, Kohji Noguchi, Sayuri Minowa, Harumi Shibata, Yoshinori Ito, Kiyohiko Hatake, Keisuke Aiba, Shunji Takahashi, Yoshikazu Sugimoto. (2007) Retroviral Integration Site Analysis and the Fate of Transduced Clones in an MDR1 Gene Therapy Protocol Targeting Metastatic Breast Cancer. Human Gene Therapy 18:10, 895-906
CrossRef220
D Tiwari, F Gao, J Hidalgo, D R Adkins, R Vij, J F DiPersio, H J Khoury. (2007) Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplantation 40:7, 671-675
CrossRef221
Jean-Emmanuel Filmont, Christian Gisselbrecht, Xavier Cuenca, Laure Deville, Marjan Ertault, Pauline Brice, Eric De Kerviler, Josette Briere, Jérome Larghero, Jean-Luc Moretti, Nicolas Mounier. (2007) The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 110:6, 1361-1369
CrossRef222
H F Fernandez, M P Escalón, D Pereira, H M Lazarus. (2007) Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?. Bone Marrow Transplantation 40:6, 505-513
CrossRef223
Min Kyoung Kim, Shin Kim, Sung Sook Lee, Sun Jin Sym, Dae Ho Lee, Sang We Kim, Seongsoo Jang, Chan Jeong Park, Hyun Sook Chi, Jooryung Huh, Cheolwon Suh. (2007) Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP. Transfusion 47:8, 1447-1454
CrossRef224
Dorte Tholstrup, Peter de Nully Brown, Jesper Jurlander, Mads Hansen. (2007) Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. European Journal of Haematology 79:2, 100-106
CrossRef225
Mitchell Sabloff, Harold L. Atkins, Isabelle Bence-Bruckler, Christopher Bredeson, Dean Fergusson, Paul Genest, Harry Hopkins, Brian Hutton, Sheryl Mcdiarmid, Lothar B. Huebsch. (2007) A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular Lymphoma. Biology of Blood and Marrow Transplantation 13:8, 956-964
CrossRef226
Vikas Gupta, Christine Chen, Armand Keating. 2007. Transplantation of Haematopoietic Stem Cells. .
CrossRef227
M Tomblyn, L J Burns, B Blazar, J Wagner, C Lee, T Rogers, P McGlave, J S Miller, D J Weisdorf. (2007) Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplantation 40:2, 111-118
CrossRef228
J. O. Armitage. (2007) How I treat patients with diffuse large B-cell lymphoma. Blood 110:1, 29-36
CrossRef229
K SAVAGE. (2007) Peripheral T-cell Lymphomas. Blood Reviews 21:4, 201-216
CrossRef230
A Spencer, K Reed, C Arthur. (2007) Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Internal Medicine Journal 0:0, 070602000936001-???
CrossRef231
N. Schmitz, M. Nickelsen, A. Sureda. (2007) Hochdosistherapie bei malignen Lymphomen. Der Onkologe 13:5, 427-433
CrossRef232
Aristeidis Chaidos, Ed Kanfer, Jane F. Apperley. (2007) Risk assessment in haemotopoietic stem cell transplantation: Disease and disease stage. Best Practice & Research Clinical Haematology 20:2, 125-154
CrossRef233
Alexander Greb, Julia Bohlius, Sven Trelle, Daniel Schiefer, Carmino A. De Souza, Christian Gisselbrecht, Tanin Intragumtornchai, Ulrich Kaiser, Hanneke C. Kluin-Nelemans, Maurizio Martelli, Noel Jean Milpied, Gino Santini, Leo F. Verdonck, Umberto Vitolo, Guido Schwarzer, Andreas Engert. (2007) High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – Results of a comprehensive meta-analysis. Cancer Treatment Reviews 33:4, 338-346
CrossRef234
A J Davies. (2007) Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab. Oncogene 26:25, 3614-3628
CrossRef235
Anna M. Kirby, N. George Mikhaeel. (2007) The role of FDG PET in the management of lymphoma: what is the evidence base?. Nuclear Medicine Communications 28:5, 335-354
CrossRef236
K Kamezaki, Y Kikushige, A Numata, T Miyamoto, K Takase, H Henzan, K Aoki, K Kato, A Nonami, T Kamimura, F Arima, K Takenaka, N Harada, T Fukuda, S Hayashi, Y Ohno, T Eto, M Harada, K Nagafuji. (2007) Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. Bone Marrow Transplantation 39:9, 523-527
CrossRef237
Min Kyoung Kim, Shin Kim, Sung Sook Lee, Sun Jin Sym, Dae Ho Lee, Seongsoo Jang, Chan Jeong Park, Hyun Sook Chi, Jooryung Huh, Cheolwon Suh. (2007) High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Annals of Hematology 86:6, 435-442
CrossRef238
Avichai Shimoni, S. Tzila Zwas, Yakov Oksman, Izhar Hardan, Noga Shem-Tov, Ronit Yerushalmi, Abraham Avigdor, Isaac Ben-Bassat, Arnon Nagler. (2007) Yttrium-90–ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Experimental Hematology 35:4, 534-540
CrossRef239
Merideth M. M. Wendland, David C. Smith, Kenneth M. Boucher, Julie D. Asch, Michael A. Pulsipher, John W. Thomson, Dennis C. Shrieve, David K. Gaffney. (2007) The Impact of Involved Field Radiation Therapy in the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma With High-Dose Chemotherapy Followed by Hematopoietic Progenitor Cell Transplant. American Journal of Clinical Oncology 30:2, 156-162
CrossRef240
Rachel E. Lerner, William Thomas, Todd E. DeFor, Daniel J. Weisdorf, Linda J. Burns. (2007) The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in Second Complete or Partial Remission. Biology of Blood and Marrow Transplantation 13:4, 486-492
CrossRef241
Mark J. Bishton, Richard J. Lush, Jenny L. Byrne, Nigel H. Russell, Bronwen E. Shaw, Andrew P. Haynes. (2007) Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. British Journal of Haematology 136:5, 752-761
CrossRef242
Nicolas Mounier, Michele Spina, Christian Gisselbrecht. (2007) Modern management of non-Hodgkin lymphoma in HIV-infected patients. British Journal of Haematology 136:5, 685-698
CrossRef243
Semra Aydin, Ulrich Dührsen, Holger Nückel. (2007) Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients. Annals of Hematology 86:4, 271-276
CrossRef244
P. Schütt, J. Passon, P. Ebeling, A. Welt, S. Müller, K. Metz, T. Moritz, S. Seeber, M. R. Nowrousian. (2007) Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. European Journal of Haematology 78:2, 93-101
CrossRef245
Anskar Y. H. Leung, Raymond Liang. (2007) Targeted therapies in T-cell malignancies. Targeted Oncology 2:1, 39-47
CrossRef246
C R Hake, T A Graubert, T S Fenske. (2007) Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?. Bone Marrow Transplantation 39:2, 59-70
CrossRef247
Lijo Simpson, Stephen M. Ansell, Joseph P. Colgan, Thomas M. Habermann, David J. Inwards, Kay M. Ristow, Patrick B. Johnston, Svetomir N. Markovic, Ivana N. Micallef, Luis F. Porrata, Thomas E. Witzig. (2007) Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leukemia & Lymphoma 48:7, 1332-1337
CrossRef248
Julie M. Vose, Philip J. Bierman, Fausto R. Loberiza, Robert G. Bociek, Daniel Matso, James O. Armitage. (2007) Phase I trial of 90 Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leukemia & Lymphoma 48:4, 683-690
CrossRef249
Mathias Witzens-Harig, Conny Heilmann, Manfred Hensel, Martin Kornacker, Axel Benner, Rainer Haas, Stefan Fruehauf, Anthony D. Ho. (2007) Long-Term Follow-Up of Patients with Non-Hodgkin Lymphoma Following Myeloablative Therapy and Autologous Transplantation of CD34 + -Selected Peripheral Blood Progenitor Cells. Stem Cells 25:1, 228-235
CrossRef250
Lieselot Brepoels, Sigrid Stroobants, Gregor Verhoef. (2007) PET and PET/CT for response evaluation in lymphoma: Current practice and developments. Leukemia & Lymphoma 48:2, 270-282
CrossRef251
Sook Hee Hong, Young Seon Hong, In Sook Woo, Yoon Ho Koh, Sang Young Rho, Ji Yean Peak, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, Ji Chan Park, Jong Wook Lee, Woo Sung Min, Chun Choo Kim. (2007) Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin's Lymphoma. Cancer Research and Treatment 39:2, 54
CrossRef252
Trevor McKibbin, Julianna Burzynski, Rebecca Greene, Jose Ochoa-Bayona, T. W. Tsai, Natalie Callander, Cesar Freytes. (2007) Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen. Leukemia & Lymphoma 48:12, 2360-2366
CrossRef253
Ock Bae Ko, Shin Kim, Dae Ho Lee, Sang We Kim, Jooryung Huh, Cheolwon Suh. (2007) Rituximab and ESHAP as Second-line Therapy for Relapsed or Primary Refractory Diffuse Large B Cell Lymphoma: The Experience of a Single Center in Korea. The Korean Journal of Hematology 42:4, 309
CrossRef254
Jonathan Tward, Martha Glenn, Michael Pulsipher, Phillip Barnette, David Gaffney. (2007) Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma 48:8, 1482-1495
CrossRef255
Régis Peffault de Latour, Driss Chaoui, Jean-Henri Bourhis, Ramdane Belhocine, Sophie Park, Ollivier Legrand, Philippe Brault, Bernard Rio, F. Heshmati, Sabine Assouad, Didier Decaudin. (2007) Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: A large multicenter comparative study in patients with malignant lymphoma. Leukemia & Lymphoma 48:5, 897-904
CrossRef256
Mark R. Litzow. (2007) Is autologous progenitor cell mobilization getting any easier?. Leukemia & Lymphoma 48:12, 2304-2305
CrossRef257
Giuseppe Milone, Salvatore Leotta, Katia Battiato, Pamela Murgano, Salvatore Mercurio, Aurora Strano, Massimo Poidomani, Stefania Coppoletta, Elisa Mauro, Giuseppe Avola, Valeria Pinto, Maria Grazia Camuglia, Rosario Giustolisi. (2007) Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m 2 plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients. Leukemia & Lymphoma 48:10, 1950-1960
CrossRef258
Soon-Thye Lim, L. Fayad, A. Tulpule, M. Modiano, F. Cabanillas, B. Laffranchi, C. Allievi, A. Bernareggi, Alexandra M. Levine. (2007) A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma 48:2, 374-380
CrossRef259
Johannes Atta, Kai U. Chow, Eckhart Weidmann, Paris S. Mitrou, Dieter Hoelzer, Hans Martin. (2007) Dexa-BEAM as salvage therapy in patients with primary refractory aggressive Non-Hodgkin lymphoma. Leukemia & Lymphoma 48:2, 349-356
CrossRef260
Bruce A. Peterson, Jeffrey Johnson, Margaret A. Shipp, Maurice Barcos, Jon P. Gockerman, George P. Canellos, For the Cancer and Leukemia Group B. (2007) High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. Leukemia & Lymphoma 48:5, 870-880
CrossRef261
Avichai Shimoni, Arnon Nagler. (2007) Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma. Leukemia & Lymphoma 48:11, 2110-2120
CrossRef262
G. Velikova, J. Weis, M.J. Hjermstad, M. Kopp, P. Morris, M. Watson, O. Sezer. (2007) The EORTC QLQ-HDC29: A supplementary module assessing the quality of life during and after high-dose chemotherapy and stem cell transplantation. European Journal of Cancer 43:1, 87-94
CrossRef263
Michal Sieniawski, Oliver Staak, Jan-Peter Glossmann, Thorsten Reineke, Helena Scheuß, Volker Diehl, Andreas Engert, Andreas Josting. (2006) Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Annals of Hematology 86:2, 107-115
CrossRef264
David J. Inwards, Jeffrey C. Cilley, Jane N. Winter. (2006) Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma. Best Practice & Research Clinical Haematology 19:4, 669-684
CrossRef265
Selmin Ataergin, Fikret Arpaci, Murat Beyzadeoglu, Mukerrem Safali, Ahmet Ozet. (2006) A long-lasting third complete remission after second autologous transplant followed by maintenance treatment with rituximab in a patient with diffuse large cell non-Hodgkin's lymphoma. American Journal of Hematology 81:12, 986-987
CrossRef266
E Jantunen. (2006) Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplantation 38:11, 715-720
CrossRef267
Georg Hess, Thomas Flohr, Karin Kolbe, Sarah Bonn, Martin Schuler, Hans Günter Derigs, Christoph Huber. (2006) Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin’s lymphoma. Annals of Hematology 85:11, 769-779
CrossRef268
Sung Chul Won, Jung Woo Han, Seung Yeon Kwon, Hee-Young Shin, Hyo-Seop Ahn, Tae Ju Hwang, Woo Ick Yang, Chuhl Joo Lyu. (2006) Autologous peripheral blood stem cell transplantation in children with non-Hodgkin’s lymphoma: a report from the Korean society of pediatric hematology-oncology. Annals of Hematology 85:11, 787-794
CrossRef269
Auayporn Nademanee, Stephen J. Forman. (2006) Role of Hematopoietic Stem Cell Transplantation for Advanced-Stage Diffuse Large Cell B-Cell Lymphoma-B. Seminars in Hematology 43:4, 240-250
CrossRef270
Gerhard Held, Joerg Schubert, Marcel Reiser, Michael Pfreundschuh. (2006) Dose-Intensified Treatment of Advanced-Stage Diffuse Large B-Cell Lymphomas. Seminars in Hematology 43:4, 221-229
CrossRef271
Ivan Aksentijevich, Richard J. Jones, Richard F. Ambinder, Elizabeth Garrett-Mayer, Ian W. Flinn. (2006) Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma. Biology of Blood and Marrow Transplantation 12:9, 965-972
CrossRef272
Caroline M Behler, Lawrence D Kaplan. (2006) Advances in the management of HIV-related non-Hodgkin lymphoma. Current Opinion in Oncology 18:5, 437-443
CrossRef273
A Nosari, R Cairoli, D Ciapanna, L Gargantini, L Intropido, C Baraté, B Scarpati, L Santoleri, G Nador, L Pezzetti, E Morra. (2006) Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. Bone Marrow Transplantation 38:6, 413-416
CrossRef274
Lode J Swinnen. (2006) Early treatment intensification for aggressive non-Hodgkinʼs lymphoma. Current Opinion in Oncology 18:5, 415-416
CrossRef275
J Shortt, A Spencer. (2006) Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplantation 38:6, 433-436
CrossRef276
J Shi, A Kahle, J W B Hershey, B M Honchak, J A Warneke, S P L Leong, M A Nelson. (2006) Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells. Oncogene 25:35, 4923-4936
CrossRef277
J Svoboda, C Andreadis, R Elstrom, E A Chong, L H Downs, A Berkowitz, S M Luger, D L Porter, S Nasta, D Tsai, A W Loren, D L Siegel, E Glatstein, A Alavi, E A Stadtmauer, S J Schuster. (2006) Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplantation 38:3, 211-216
CrossRef278
L. Pierelli, M. Maresca, N. Piccirillo, S. Pupella, M. Gozzer, M. L. Foddai, M. Vacca, G. Adorno, U. Coppetelli, U. Paladini. (2006) Accurate prediction of autologous stem cell apheresis yields using a double variable-dependent method assures systematic efficiency control of continuous flow collection procedures. Vox Sanguinis 91:2, 126-134
CrossRef279
ISAO HARA, HIDEAKI MIYAKE, YUJI YAMADA, ATSUSHI TAKENAKA, MASATO FUJISAWA. (2006) High-dose chemotherapy for male germ cell tumor. International Journal of Urology 13:8, 1037-1044
CrossRef280
P Quittet, P Ceballos, E Lopez, Z Y Lu, P Latry, C Becht, E Legouffe, N Fegueux, C Exbrayat, D Pouessel, V Rouillé, J P Daures, B Klein, J F Rossi. (2006) Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients. Bone Marrow Transplantation 38:4, 275-284
CrossRef281
Leona A. Holmberg, F. Marc Stewart. (2006) Revisiting the role of dose intensity in hematological malignancies. Experimental Hematology 34:7, 811-825
CrossRef282
Tarun Kewalramani, Andrew D. Zelenetz, Julie Teruya-Feldstein, Paul Hamlin, Joachim Yahalom, Steven Horwitz, Stephen D. Nimer, Craig H. Moskowitz. (2006) Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. British Journal of Haematology 134:2, 202-207
CrossRef283
Charu Aggarwal, Sameer Gupta, William P. Vaughan, Gene B. Saylors, Donna E. Salzman, Rhonda O. Katz, Amy G. Nance, Arabella B. Tilden, Matthew H. Carabasi. (2006) Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen. Biology of Blood and Marrow Transplantation 12:7, 770-777
CrossRef284
Suleyman Alici, Sevil Bavbek, Mert Basaran, Haluk Onat. (2006) Prognostic factors in patients with aggressive non-Hodgkin’s lymphoma without complete response to first-line therapy. Advances in Therapy 23:4, 534-542
CrossRef285
G. Held, J. Schubert, C. Rübe, M. Pfreundschuh. (2006) Fortschritte in der Behandlung der diffus-großzelligen Lymphome. Der Onkologe 12:7, 619-627
CrossRef286
Lisa Y. Law, Sandra J. Horning, Ruby M. Wong, Laura J. Johnston, Ginna G. Laport, Robert Lowsky, Judith A. Shizuru, Karl G. Blume, Robert S. Negrin, Keith E. Stockerl-Goldstein. (2006) High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 12:7, 703-711
CrossRef287
Felicetto Ferrara, Assunta Viola, Carolina Copia, Ettore Mariano Schiavone, Maria Celentano, Filiberto Pollio, Maria Rosaria D'Amico, Salvatore Palmieri. (2006) Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation. Hematological Oncology 24:2, 73-77
CrossRef288
F K Buadi, I N Micallef, S M Ansell, L F Porrata, A Dispenzieri, M A Elliot, D A Gastineau, M A Gertz, M Q Lacy, M R Litzow, A Tefferi, D J Inwards. (2006) Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplantation 37:11, 1017-1022
CrossRef289
Amrita Krishnan, Auayporn Nademanee, Henry Fung, Maria Angelopoulou, Arturo Molina, Karl Gaal, Andrew Dagis, Joycelynne Palmer, Joseph Alvarnas, Marilyn Slovak, Neil Kogut, Leslie Popplewell, Roberto Rodriguez, Jeffrey Schriber, Sean Wang, Stephen J. Forman. (2006) Does Follicularity in Large Cell Lymphoma Predict Outcome after Autologous Stem Cell Transplantation?. Biology of Blood and Marrow Transplantation 12:6, 641-647
CrossRef290
Parham Khosravi Shahi, Gumersindo Pérez Manga. (2006) Linfoma B difuso de células grandes. Medicina Clínica 127:1, 17-21
CrossRef291
Shernan G. Holtan, Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Mark R. Litzow, Dennis A. Gastineau, Svetomir N. Markovic. (2006) Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. British Journal of Haematology 133:6, 628-633
CrossRef292
Juliana Pereira, Marcelo Bellesso, Luis Fernando Pracchia, Abrahão Elias Hallack Neto, Beatriz Beitler, Maria Cristina Martins de Almeida Macedo, Lucia Cristina Santos Dias, Pedro Enrique Dorlhiac-Llacer, Frederico Luiz Dulley, Dalton Chamone. (2006) Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: The experience of a single center in Brazil. Leukemia Research 30:6, 681-685
CrossRef293
A Gratwohl, H Baldomero, K Frauendorfer, A Urbano-Ispizua. (2006) EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplantation 37:12, 1069-1085
CrossRef294
C Joao, L F Porrata, D J Inwards, S M Ansell, I N Micallef, P B Johnston, D A Gastineau, S N Markovic. (2006) Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplantation 37:9, 865-871
CrossRef295
R. Marks, J. Finke. (2006) Die Bedeutung der Stammzelltherapie in der Hämatologie und Onkologie. Der Internist 47:5, 467-478
CrossRef296
Willis H. Navarro, Fausto R. Loberiza, Ruta Bajorunaite, Koen van Besien, Julie M. Vose, Hillard M. Lazarus, J. Douglas Rizzo. (2006) Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 12:5, 541-551
CrossRef297
Copelan, Edward A., . (2006) Hematopoietic Stem-Cell Transplantation. New England Journal of Medicine 354:17, 1813-1826
Full Text298
Larry Boehlke, Jane N Winter. (2006) Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug. Expert Opinion on Biological Therapy 6:4, 409-415
CrossRef299
Barbel Seyfarth, Andreas Josting, Martin Dreyling, Norbert Schmitz. (2006) Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. British Journal of Haematology 133:1, 3-18
CrossRef300
Federica Sorá, Nicola Piccirillo, Patrizia Chiusolo, Luca Laurenti, Roberto Marra, Francesco Bartolozzi, Giuseppe Leone, Simona Sica. (2006) Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation. Cancer 106:4, 859-866
CrossRef301
E Jantunen, M Itälä, E Juvonen, S Leppä, L Keskinen, K Vasala, K Remes, T Wiklund, E Elonen, T Nousiainen. (2006) Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplantation 37:4, 367-372
CrossRef302
Pascale Frere, Maguy Pereira, Georges Fillet, Yves Beguin. (2006) Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. European Journal of Haematology 76:2, 102-108
CrossRef303
A P Rapoport. (2006) Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come. Bone Marrow Transplantation 37:3, 239-247
CrossRef304
Grace Wu, Armand Keating. (2006) Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. Cancer 106:2, 247-257
CrossRef305
Yeon Hee Park. (2006) What is the best treatment for primary breast lymphoma? Combined modality should be adapted according to the risk stratification. Leukemia & Lymphoma 47:10, 2011-2012
CrossRef306
R.C. Baldissera, M. Nucci, A.C. Vigorito, A. Maiolino, B.P. Simões, I. Lorand-Metze, F.J.P. Aranha, E.C.M. Miranda, K.B.B. Pagnano, M.A. Ruiz, A.A.J.G. Moraes, C.A. De Souza. (2006) Frontline Therapy with Early Intensification and Autologous Stem Cell Transplantation versus Conventional Chemotherapy in Unselected High-Risk, Aggressive Non-Hodgkin’s Lymphoma Patients: A Prospective Randomized GEMOH Report. Acta Haematologica 115:1-2, 15-21
CrossRef307
Tanin Intragumtornchai, Udomsak Bunworasate, Thanyaphong Na Nakorn, Ponlapat Rojnuckarin. (2006) Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma 47:7, 1306-1314
CrossRef308
Hyun Chang, June-Won Cheong, Jee-Sook Hahn. (2006) High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma: an Eight-Year Experience. Yonsei Medical Journal 47:5, 604
CrossRef309
Edgardo S. Santos, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Luis E. Raez. (2006) Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Leukemia & Lymphoma 47:12, 2453-2476
CrossRef310
Noemí Puig, Javier De La Rubia, María J. Remigia, Isidro Jarque, Guillermo Martín, Luca Cupelli, Guillermo F. Sanz, Ignacio Lorenzo, Jaime Sanz, Jesús A. Martínez, Carmen Jiménez, Miguel A. Sanz. (2006) Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leukemia & Lymphoma 47:8, 1488-1494
CrossRef311
Ulrich J. M. Mey, Attilio Olivieri, Katjana S. Orlopp, Christian Rabe, John W. Strehl, Marcus Gorschlueter, Manfred Hensel, Dimitri Flieger, Axel G. Glasmacher, Ingo G. H. Schmidt-Wolf. (2006) DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leukemia & Lymphoma 47:12, 2558-2566
CrossRef312
Nicola Di Renzo, Maura Brugiatelli, Antonella Montanini, Maria Luigia Vigliotti, Giulia Cervetti, Anna Marina Liberati, Stefano Luminari, Pierangelo Spedini, Gianfranco Giglio, Massimo Federico. (2006) Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. Leukemia & Lymphoma 47:3, 473-479
CrossRef313
Sonali M. Smith, Jeffrey L. Johnson, Donna Niedzwiecki, J. Paul Eder, George Canellos, Bruce D. Cheson, Nancy L. Bartlett, for the Cancer and Leukemia Group B. (2006) Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906. Leukemia & Lymphoma 47:8, 1511-1517
CrossRef314
Sagar Lonial, Martha Arellano, Donald Hutcherson, Amelia Langston, Christopher Flowers, L. T. Heffner, Elliott Winton, Mary Jo Lechowicz, Edmund K. Waller. (2006) Results of a clinical phase I dose-escalation study of cytarabinein combination with fixed-dose vinorelbine, paclitaxel, etoposideand cisplatin for the treatment of relapsed/refractory lymphoma. Leukemia & Lymphoma 47:10, 2155-2162
CrossRef315
Willem J. Heeckeren, Jennifer Vollweiler, Pingfu Fu, Brenda W. Cooper, Howard Meyerson, Hillard M. Lazarus, Alexandra Simic, Mary J. Laughlin, Stanton L. Gerson, Omer N. Koc. (2006) Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device. British Journal of Haematology 132:1, 42-55
CrossRef316
Chitra Hosing, Rima M. Saliba, Martin Körbling, Sandra Acholonu, John Mcmannis, Paolo Anderlini, Sergio Giralt, Marcos De Lima, Grace-Julia Okoroji, Daniel R. Couriel, Richard Champlin, Issa F. Khouri, Michele L. Donato. (2006) High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leukemia & Lymphoma 47:7, 1290-1294
CrossRef317
Basak Oyan, Yener Koc, Evren Ozdemir, Ayse Kars, Alev Turker, Gulten Tekuzman, Emin Kansu. (2006) High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leukemia & Lymphoma 47:8, 1545-1552
CrossRef318
Rodrigo Ruiz-Soto, Guillaume Sergent, Christian Gisselbrecht, Jerome Larghero, Marjan Ertault, Christophe Hennequin, Julien Manson, Eric de Kerviler, Josette Briere, Nicolas Mounier. (2005) Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Cancer 104:12, 2735-2742
CrossRef319
Richard T. Doocey, Cynthia L. Toze, Joseph M. Connors, Thomas J. Nevill, Randy D. Gascoyne, Michael J. Barnett, Donna L. Forrest, Donna E. Hogge, Julye C. Lavoie, Stephen H. Nantel, John D. Shepherd, Heather J. Sutherland, Nicholas J. Voss, Clayton A. Smith, Kevin W. Song. (2005) Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma*. British Journal of Haematology 131:2, 223-230
CrossRef320
Marc C. Chamberlain, Craig Nolan, Lauren E. Abrey. (2005) Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. Journal of Neuro-Oncology 75:1, 71-83
CrossRef321
Basak Oyan, Yener Koc, Evren Ozdemir, Ayse Kars, Alev Turker, Gulten Tekuzman, Emin Kansu. (2005) Ifosfamide, Idarubicin, and Etoposide in Relapsed/Refractory Hodgkin Disease or Non-Hodgkin Lymphoma: A Salvage Regimen with High Response Rates before Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 11:9, 688-697
CrossRef322
T. Kuittinen, T. Wiklund, K. Remes, E. Elonen, T. Lehtinen, O. Kuittinen, S. Leppa, M. Putkonen, R. Raty, T. Turpeenniemi-Hujanen, T. Nousiainen, E. Jantunen. (2005) Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey. European Journal of Haematology 75:3, 199-205
CrossRef323
Shannon T. Kahn, Christopher R. Flowers, Mary Jo Lechowicz, Kathryn Hollenbach, Peter A.S. Johnstone. (2005) Refractory or Relapsed Hodgkin??s Disease and Non-Hodgkin??s Lymphoma. The Cancer Journal 11:5, 425-431
CrossRef324
Jiaqi Shi, Mark A. Nelson. (2005) The cyclin-dependent kinase 11 interacts with NOT2. Biochemical and Biophysical Research Communications 334:4, 1310-1316
CrossRef325
J A Gutman, S I Bearman, Y Nieto, J W Sweetenham, R B Jones, E J Shpall, C Zeng, A Baron, P A McSweeney. (2005) Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. Bone Marrow Transplantation 36:5, 443-451
CrossRef326
Efstathios S. Papageorgiou, Panagiotis Tsirigotis, Meletios Dimopoulos, Nikolaos Pavlidis, George Fountzilas, Sotirios Papageorgiou, Theofanis Economopoulos. (2005) Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. European Journal of Haematology 75:2, 124-129
CrossRef327
Kirit M. Ardeshna, Nicholaos Kakouros, Wendi Qian, Michael G. Powell, Nishaat Saini, Shirley D'Sa, Stephen Mackinnon, Peter J. Hoskin, Anthony H. Goldstone, David C. Linch. (2005) Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. British Journal of Haematology 130:3, 363-372
CrossRef328
Jan-Peter Glossmann, Jan Oliver Staak, Lucia Nogova, Volker Diehl, Christoph Scheid, Jens Kisro, Hans-Edgar Reis, Norma Peter, Andreas Engert, Andreas Josting. (2005) Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma. Annals of Hematology 84:8, 517-525
CrossRef329
Carole Soussain, Khê Hoang-Xuan, Nancy D. Doolittle. (2005) New Treatment Approaches in Primary Central Nervous System Lymphoma. Hematology/Oncology Clinics of North America 19:4, 719-728
CrossRef330
S. M. Ansell, J. Armitage. (2005) Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic Proceedings 80:8, 1087-1097
CrossRef331
Jennie H. Best, John Hornberger, Stephen J. Proctor, Louis F. Omnes, Fred Jost. (2005) Cost-Effectiveness Analysis of Rituximab Combined with CHOP for Treatment of Diffuse Large B-Cell Lymphoma. Value in Health 8:4, 462-470
CrossRef332
B W Butcher, R H Collins. (2005) The graft-versus-lymphoma effect: clinical review and future opportunities. Bone Marrow Transplantation 36:1, 1-17
CrossRef333
David Nachbaur, Hildegard T. Greinix, Elisabeth Koller, Otto Krieger, Werner Linkesch, Hedwig Kasparu, Michael Pober, Wolfgang Hinterberger, Hubert Hausmaninger, Max Heistinger, Ernst Ulsperger, Susanne Karlhuber, Wolfgang Schwinger, Beate Lindner. (2005) Long-term results of autologous stem cell transplantation for Hodgkin’s disease (HD) and low-/intermediate-grade B non-Hodgkin’s lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Annals of Hematology 84:7, 462-473
CrossRef334
Huseyin Abali, Basak Oyan, Yener Koc, Ayse Kars, Ibrahim Barista, Aysegul Uner, Alev Turker, Figen Demirkazik, Fatma Tekin, Gulten Tekuzman, Emin Kansu. (2005) IIVP Salvage Regimen Induces High Response Rates in Patients With Relapsed Lymphoma Before Autologous Stem Cell Transplantation. American Journal of Clinical Oncology 28:3, 264-269
CrossRef335
Antonino Musolino, Maria Antonietta Perrone, Maria Michiara, Daniela Delnevo, Vittorio Franciosi, Beatrice Di Blasio, Guido Ceci, Roberta Camisa, Andrea Ardizzoni, Giorgio Cocconi. (2005) Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Cancer 103:10, 2109-2117
CrossRef336
A Gratwohl, J Passweg, C Bocelli-Tyndall, A Fassas, J M van Laar, D Farge, M Andolina, R Arnold, E Carreras, J Finke, I Kötter, T Kozak, I Lisukov, B Löwenberg, A Marmont, J Moore, R Saccardi, J A Snowden, F van den Hoogen, N M Wulffraat, X W Zhao, A Tyndall. (2005) Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplantation 35:9, 869-879
CrossRef337
M Ng, J Waters, D Cunningham, I Chau, A Horwich, M Hill, A R Norman, A Wotherspoon, D Catovsky. (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. British Journal of Cancer 92:8, 1352-1357
CrossRef338
David Serrano, Rafael Carrión, Pascual Balsalobre, Pilar Miralles, Juan Berenguer, Ismael Buño, Alfonso Gómez-Pineda, José M. Ribera, Eulogio Conde, José L. Díez-Martín. (2005) HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Experimental Hematology 33:4, 487-494
CrossRef339
Corrado Tarella, Alessandro M Gianni. (2005) Bone marrow transplantation for lymphoma CR1. Current Opinion in Oncology 17:2, 99-105
CrossRef340
Stephen J. Forman. (2005) Innovations in autologous transplantation for hematologic malignancy. Biology of Blood and Marrow Transplantation 11:2, 28-33
CrossRef341
Carolyn Featherstone, Geoff Delaney, Susannah Jacob, Michael Barton. (2005) Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence. Cancer 103:2, 383-392
CrossRef342
JJ Biagi, KE Herbert, C Smith, E Abdi, M Leahy, C Falkson, M Wolf, H Januszewicz, JF Seymour, K Richards, JP Matthews, B Dale, HM Prince. (2005) A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leukemia & Lymphoma 46:2, 197-206
CrossRef343
E Jabbour, N Peslin, P Arnaud, C Ferme, P Carde, JM Vantelon, C Bocaccio, JH Bourhis, S Koscielny, V Ribrag. (2005) Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation. Leukemia & Lymphoma 46:6, 861-867
CrossRef344
Michael J. Robertson, Rafat Abonour, Robert Hromas, Robert P. Nelson, Naomi S. Fineberg, Kenneth Cornetta. (2005) Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma 46:10, 1477-1487
CrossRef345
Michael Pfreundschuh. (2005) Management of Diffuse Large B-Cell Lymphoma in Young Patients. American Journal of Cancer 4:6, 349-357
CrossRef346
Pazit Kanter, Aliza Zeidman, Jonathan Streifler, Victor Marmelstein, Einat Even-Sapir, Ur Metser, Gideon Y. Stein, Amos M. Cohen. (2005) PET-CT imaging of combined brachial and lumbosacral neurolymphomatosis. European Journal of Haematology 74:1, 66-69
CrossRef347
Pier Luigi Zinzani. (2005) Autologous Hematopoietic Stem Cell Transplantation in Non-Hodgkin’s Lymphomas. Acta Haematologica 114:4, 255-259
CrossRef348
Karl S. Peggs, Stephen Mackinnon, David C. Linch. (2005) The role of allogeneic transplantation in non-Hodgkin's lymphoma. British Journal of Haematology 128:2, 153-168
CrossRef349
Lapo Alinari, Gerardo Musuraca, Monica Tani, Vittorio Stefoni, Annalisa Gabriele, Enrica Marchi, Mariapaola Fina, Antonio De Vivo, Stefano Pileri, Michele Baccarani, Pier Luigi Zinzani. (2005) Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. Leukemia & Lymphoma 46:10, 1437-1440
CrossRef350
T Ahmed, K Rashid, F Waheed, R Kancherla, Z Qureshi, A Hoang, J Richter, MF Ali, R Goldberg, D Liu, K Seiter. (2005) Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant. Leukemia & Lymphoma 46:3, 405-414
CrossRef351
Ja Eun Koo, Min-Hee Ryu, Hee-Jeong Shon, Hye-Jin Kang, Woo-Kun Kim, Cheolwon Suh, Jung-Shin Lee, Yoon-Koo Kang. (2005) Three Cases Treated with High-dose Cytarabine and Etoposide followed by Autologous Stem Cell Transplantation for Relapsed Primary CNS Lymphoma. The Korean Journal of Hematology 40:3, 172
CrossRef352
Ulrich Herrlinger, Agnieszka Korfel, Holger Hebart, Uwe Schlegel, Ludwig Plasswilm, Gerald Illerhaus, J
rgen Finke, William Kr
CrossRef353
Soo-Mee Bang, Yeo-Kyeoung Kim, Yeon Hee Park, Sang Kyun Sohn, Je-Jung Lee, Eun Kyung Cho, Baek-Yeol Ryoo, Ik-Joo Chung, Sung-Soo Yoon, Hyeoung-Joon Kim, Jae Hoon Lee, Hwi-Joong Yoon, Seonyang Park. (2005) High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma. Leukemia & Lymphoma 46:11, 1599-1604
CrossRef354
Kevin W Song, Peter N Mollee, Donna E Hogge, Vikas Gupta, Michael J Barnett, Donna L Forrest, Julye C Lavoie, Thomas J Nevill, Stephen H Nantel, John D Shepherd, Clay A Smith, Heather J Sutherland, Cynthia L Toze, Michael Crump, Armand Keating. (2005) Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leukemia & Lymphoma 46:4, 525-531
CrossRef355
Jeffrey L Halaas, Craig H Moskowitz, Steven Horwitz, Carol Portlock, Ariela Noy, David Straus, Owen A O'Connor, Joachim Yahalom, Andrew D Zelenetz. (2005) R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy. Leukemia & Lymphoma 46:4, 541-547
CrossRef356
Xingwei Sui, William Bensinger, Oliver Press. (2005) Improved Conditioning Regimens for Autologous Transplantation Using Targeted Radiotherapy. Acta Haematologica 114:4, 230-238
CrossRef357
Eric Jacobsen, Arnold Freedman. (2004) B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. The Lancet Oncology 5:12, 711-717
CrossRef358
Michel van Agthoven, Carin A Uyl-de Groot, Pieter Sonneveld, Anton Hagenbeek. (2004) Economic assessment in the management of non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 5:12, 2529-2548
CrossRef359
B. Hertenstein, A. Ganser. (2004) Knochenmarktransplantation. Der Internist 45:11, 1261-1267
CrossRef360
Hossein Borghaei, Michael Millenson, Russell Schilder, Mitchell Alden, Andre Rogatko, Hao Wang, Kristin Padavic-Shaller, Mitchell R. Smith. (2004) Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. Cancer 101:9, 2034-2041
CrossRef361
Barry R. Goldspiel. (2004) Chemotherapy Dose Density in Early-Stage Breast Cancer and Non-Hodgkin’s Lymphoma. Pharmacotherapy 24:10, 1347-1357
CrossRef362
Jerkeman M., Leppa S., Kvaloy S., Holte H.. (2004) ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma - the Nordic Lymphoma Group experience. European Journal of Haematology 73:3, 179-182
CrossRef363
Cecilia Simonelli, Mariagrazia Michieli, Rosamaria Tedeschi, Maurizio Rupolo, Luciano Abbruzzese, Ivana Sartor, Valter Gattei, Michele Spina, Paolo De Paoli, Umberto Tirelli. (2004) Hepatitis C virus infection does not prevent autologous bone marrow transplantation in HIV-related non-Hodgkin's lymphoma. AIDS 18:13, 1859-1861
CrossRef364
H. Miles Prince, Paul J. Simmons, Genevieve Whitty, Dominic P. Wall, Lesley Barber, Guy C. Toner, John F. Seymour, Gary Richardson, Robert Mrongovius, David N. Haylock. (2004) Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells*. British Journal of Haematology 126:4, 536-545
CrossRef365
Maria A Foncillas, Miguel A Diaz, Juli??n Sevilla, Marta Gonzalez Vicent, Sandra Fernandez-Plaza, Antonio P??rez, Luis Madero. (2004) Engraftment Syndrome Emerges as the Main Cause of Transplant-Related Mortality in Pediatric Patients Receiving Autologous Peripheral Blood Progenitor Cell Transplantation. Journal of Pediatric Hematology/Oncology 26:8, 492-496
CrossRef366
Andrew M. Evens, Ronald B. Gartenhaus. (2004) Treatment of T-cell non-hodgkin’ lymphoma. Current Treatment Options in Oncology 5:4, 289-303
CrossRef367
A. K. Blystad, J. Delabie, S. Kvaloy, H. Holte, H. Valerhaugen, I. Ikonomou, G. Kvalheim. (2004) Infused CD34+ cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. British Journal of Haematology 125:5, 605-612
CrossRef368
Irene M. Ghobrial, Francis Buadi, Robert J. Spinner, Joseph P. Colgan, Alexandra P. Wolanskyj, P. James Dyck, Thomas E. Witzig, Ivana N. Micallef, Brian Patrick O'Neill. (2004) High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis. Cancer 100:11, 2403-2407
CrossRef369
Koen Van Besien, Rakesh Mehra, Navin Wadehra, Wendy Stock, Issa Khouri, Sergio Giralt, Steve Devine, Amittha Wickrema, David Peace, Jeff Sosman, Jim Gajewski, Richard Champlin. (2004) Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation 10:6, 386-394
CrossRef370
Bryan T Hennessy, Emer O Hanrahan, Peter A Daly. (2004) Non-Hodgkin lymphoma: an update. The Lancet Oncology 5:6, 341-353
CrossRef371
Cheolwon Suh, Hyo-Jung Kim, Sang-Hee Kim, Shin Kim, Soon-Jong Lee, Yoon-Shin Lee, Eun-Kyoung Kim, Sung-Bae Kim, Jung-Sin Lee, Michael W. Kim, Kihyun Kim, and Sung-Soo Yoon. (2004) Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses. Transfusion 44:4, 533-538
CrossRef372
Yvette L Kasamon, Richard L Wahl, Lode J Swinnen. (2004) FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy. Current Opinion in Oncology 16:2, 100-105
CrossRef373
Yago Nieto, Roy B Jones, Elizabeth J Shpall. (2004) High-dose chemotherapy for breast cancer: is another look warranted?. Current Opinion in Oncology 16:2, 114-119
CrossRef374
Jonathan W Friedberg, Richard I Fisher. (2004) Iodine-131 tositumomab (Bexxar®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 4:1, 18-26
CrossRef375
Abba C. Zubair, David Zahrieh, Heather Daley, Darlys Schott, John G. Gribben, Edwin P. Alyea, Robert Schlossman, Arnold Freedman, Joseph H. Antin, Robert J. Soiffer, Donna Neuberg, Jerome Ritz. (2004) Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion 44:2, 253-261
CrossRef376
Christian Gisselbrecht, Nicolas Mounier. (2004) Improving Second-Line Therapy in Aggressive Non-Hodgkin’s Lymphoma. Seminars in Oncology 31, 12-16
CrossRef377
Michelle M Bishop, John R Wingard. (2004) Thriving after hematopoietic stem cell transplant: a focus on positive changes in quality of life. Expert Review of Pharmacoeconomics & Outcomes Research 4:1, 111-123
CrossRef378
E Jabbour, B Chalhoub, F Suzan, S Aloulou, C Cainap, N Toumi, C Fermé, P Carde, V Ribrag. (2004) Outcome of Elderly Patients with Aggressive Non-Hodgkin's Lymphoma Refractory to or Relapsing after First-line CHOP or CHOP-like Chemotherapy: A Low Probability of Cure. Leukemia & Lymphoma 45:7, 1391-1394
CrossRef379
Barbara Pocali, Mariacarla De Simone, Mario Annunziata, Salvatore Palmieri, Maria Rosaria D'Amico, Carolina Copia, Assunta Viola, Giuseppina Mele, Ettore Mariano Schiavone, Felicetto Ferrara. (2004) Ifosfamide, Epirubicin and Etoposide (IEV) Regimen as Salvage and Mobilization Therapy for Refractory or Early Relapsing Patients with Aggressive Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 45:8, 1605-1609
CrossRef380
Pier Luigi Zinzani, Monica Tani, Annalisa Gabriele, Filippo Gherlinzoni, Antonello de Vivo, Paolo Ricci, Giuseppe Bandini, Roberto Massimo Lemoli, Maria Rosa Motta, Simonetta Rizzi, Valeria Guidice, Maurizio Zompatori, Vittorio Stefoni, Lapo Alinari, Gerardo Musuraca, Enrica Marchi, Simona Bassi, Roberto Conte, Stefano Pileri, Sante Tura, Michele Baccarani. (2004) High-Dose Therapy with Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: The Bologna Experience. Leukemia & Lymphoma 45:2, 321-326
CrossRef381
Attilio Olivieri, Marino Brunori, Debora Capelli, Mauro Montanari, Danilo Massidda, Guido Gini, Moira Lucesole, Antonella Poloni, Massimo Offidani, Marco Candela, Riccardo Centurioni, Pietro Leoni. (2004) Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. European Journal of Haematology 72:1, 10-17
CrossRef382
F Waheed, R Kancherla, K Seiter, D Liu, Z Qureshi, A Hoang, T Ahmed. (2004) High Dose Chemotherapy with Thiotepa, Mitoxantrone and Carboplatin (TMJ) Followed by Autologous Stem Cell Support in 100 Consecutive Lymphoma Patients in a Single Centre: Analysis of Efficacy, Toxicity and Prognostic Factors. Leukemia & Lymphoma 45:11, 2253-2259
CrossRef383
Massimo Libra, Valli De Re, Annunziata Gloghini, Patrick Michael Navolanic, Antonino Carbone, Mauro Boiocchi. (2004) Second Primary Lymphoma or Recurrence: A Dilemma Solved by VDJ Rearrangement Analysis. Leukemia & Lymphoma 45:8, 1539-1543
CrossRef384
Stephen M Beard, Lucy Wall, Louise Gaffney, Fiona Sampson. (2004) Aggressive Non-Hodgkin???s Lymphoma. PharmacoEconomics 22:4, 207-224
CrossRef385
Michael Boyiadzis, Steven Pavletic. (2004) Haematopoietic stem cell transplantation: indications, clinical developments and future directions. Expert Opinion on Pharmacotherapy 5:1, 97-108
CrossRef386
JENNIFER R BROWN, GUYLAINE GAUDET, JONATHAN W FRIEDBERG, DONNA NEUBERG, PETER MAUCH, JEFFREY L KUTOK, TAK TAKVORIAN, DAVID C FISHER, JOHN G GRIBBEN, HELEN KIM, LEE M NADLER, ARNOLD S FREEDMAN. (2004) Autologous Bone Marrow Transplantation for Marginal Zone Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 45:2, 315-320
CrossRef387
Madan Jagasia, David Morgan, Stacey Goodman, Katherine Hamilton, Marsha Kinney, Yu Shyr, Richard Stein, John Zic, John Greer. (2004) Histology Impacts the Outcome of Peripheral T-Cell Lymphomas after High Dose Chemotherapy and Stem Cell Transplant. Leukemia & Lymphoma 45:11, 2261-2267
CrossRef388
Yu Oyama, Joan Guitart, Timothy M Kuzel, Richard K Burt, Steven T Rosen. (2003) High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematology/Oncology Clinics of North America 17:6, 1475-1483
CrossRef389
Arturo Molina, John Zaia, Amrita Krishnan. (2003) Treatment of human immunodeficiency virus-related lymphoma with haematopoietic stem cell transplantation. Blood Reviews 17:4, 249-258
CrossRef390
Helen McCarthy, Christian H. Ottensmeier, Terry J. Hamblin, Freda K. Stevenson. (2003) Anti-idiotype vaccines. British Journal of Haematology 123:5, 770-781
CrossRef391
Josette Bou-Khalil, Michal Rose, Amanda Psyrri, Elizabeth D'Andrea, Erin Medoff, Carol Staugaard-Hahn, Christine Holtkamp, Susan Gran, John Pezzimente, Edward Snyder, Dennis Cooper, Bruce Haffty, Michael Reiss, Barbara Burtness. (2003) Sequential High-Dose Alkylating Therapy and Stem Cell Support for High-Risk Stage III Breast Cancer. The Breast Journal 9:6, 472-477
CrossRef392
Pier Luigi Zinzani. (2003) Traditional Treatment Approaches in B-cell Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 44:S4, S6-S14
CrossRef393
Robert Marcus. (2003) Current Treatment Options in Aggressive Lymphoma. Leukemia & Lymphoma 44:S4, S15-S27
CrossRef394
Takayuki Ishikawa. (2003) Current Status of Therapeutic Approaches to Adult T-Cell Leukemia. International Journal of Hematology 78:4, 304-311
CrossRef395
Bart Schot, Gustaaf van Imhoff, Jan Pruim, Wim Sluiter, Willem Vaalburg, Edo Vellenga. (2003) Predictive value of early 18 F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. British Journal of Haematology 123:2, 282-287
CrossRef396
Massimo Magagnoli, Luca Castagna, Monica Balzarotti, Barbara Sarina, Inna Timofeeva, Alexia Bertuzzi, Silvana Compasso, Andrea Nozza, Licia Siracusano, Armando Santoro. (2003) Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: Survey from a single institution. American Journal of Hematology 73:4, 267-272
CrossRef397
Avichai Shimoni, Izhar Hardan, Abraham Avigdor, Moshe Yeshurun, Pia Raanani, Isaac Ben-Bassat, Arnon Nagler. (2003) Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. British Journal of Haematology 122:3, 457-464
CrossRef398
Anne Beauchamp-Nicoud, Danielle Feneux, Chantal Bayle, Alain Bernheim, Claude L
CrossRef399
Thomas C. Shea, Rebecca Bruner, Joseph M. Wiley, Jonathan S. Serody, Scott Sailer, Don A. Gabriel, Eileen Capel, Dominic T. Moore, Georgette Dent, Stuart Bentley, Mark E. Brecher. (2003) An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies. Biology of Blood and Marrow Transplantation 9:7, 443-452
CrossRef400
Michinori Ogura, Yoshitoyo Kagami, Hirofumi Taji, Ritsuro Suzuki, Kazuhisa Miura, Takahiro Takeuchi, Yasuo Morishima. (2003) Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma. International Journal of Hematology 77:5, 503-511
CrossRef401
Marcie Tomblyn, Jane N Winter. (2003) Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 3:3, 281-294
CrossRef402
Jacob D Bitran, Leonard Klein, Doreen Link, Jane Kosirog-Glowacki, Cynthia Stewart, David Raack, Pat Sheahan, Josephine Lisowski, Josie Rowen. (2003) High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biology of Blood and Marrow Transplantation 9:6, 383-388
CrossRef403
Ruth Pettengell, David Linch. (2003) Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. British Journal of Haematology 121:1, 44-48
CrossRef404
Ian Chau, Mark Harries, David Cunningham, Mark Hill, Paul J. Ross, Caroline D. Archer, Andrew R. Norman, Andrew Wotherspoon, Dow Mu Koh, Kairen Gill, Maggie Uzzell, Yvonne Prior, Daniel Catovsky. (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. British Journal of Haematology 120:6, 970-977
CrossRef405
Kevin W. Song, Peter Mollee, Armand Keating, Michael Crump. (2003) Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. British Journal of Haematology 120:6, 978-985
CrossRef406
Bertrand Coiffier. (2003) Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly. Seminars in Oncology 30:1, 21-27
CrossRef407
Christian Gisselbrecht, Nicolas Mounier. (2003) Rituximab: Enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma. Seminars in Oncology 30:1, 28-33
CrossRef408
Frederick R. Appelbaum. (2003) The Current Status of Hematopoietic Cell Transplantation. Annual Review of Medicine 54:1, 491-512
CrossRef409
L.N. Gordan, M.W. Sugrue, J.W. Lynch, K.D. Williams, S.A. Khan, J.R. Wingard, J.S. Moreb. (2003) Poor Mobilization of Peripheral Blood Stem Cells is a Risk Factor for Worse Outcome in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Leukemia & Lymphoma 44:5, 815-820
CrossRef410
Marc Andre, Etienne Baudoux, Dominique Bron, Jean-Luc Canon, Veronique D'Hondt, Marie-France Fassotte, Lionel D'Hondt, Georges Fillet, Yves Humblet, Guy Jerusalem, Philippe Vermeulen, Michel Symann, Yves Beguin. (2003) Phase III randomized study comparing 5 or 10 mug per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 43:1, 50-57
CrossRef411
E. Jantunen, T. Kuittinen, T. Nousiainen. (2003) BEAC or BEAM for High-dose Therapy in Patients with Non-Hodgkin's Lymphoma? A Single Centre Analysis on Toxicity and Efficacy. Leukemia & Lymphoma 44:7, 1151-1158
CrossRef412
Lotfi Benboubker, Guillaume Cartron, Françoise Roingeard, Martine Delain, Michel Degenne, Claude Linassier, Olivier Hérault, Danielle Truglio, Myrtille Bout, André Petit, Jean-Louis Brémond, Isabelle Desbois, Philippe Colombat, Christian Binet, Jorge Domenech. (2003) Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. Experimental Hematology 31:1, 89-97
CrossRef413
Mauro Montanari, Debora Capelli, Antonella Poloni, Danilo Massidda, Marino Brunori, Luca Spitaleri, Massimo Offidani, Moira Lucesole, Maria C. Masia, Florinda Balducci, Cristina Refe, Mario Piani, Pietro Leoni, Attilio Olivieri. (2003) Long-term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled-rate freezing and uncontrolled-rate freezing at 80oC. Transfusion 43:1, 42-49
CrossRef414
M. Miwa. (2002) Psychiatric Symptoms With Non-Hodgkin's Lymphoma. Psychosomatics 43:6, 507-508
CrossRef415
Amrita Krishnan, John Zaia, Arturo Molina. (2002) Stem Cell Transplantation and Gene Therapy for HIV-Related Lymphomas. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 11:5, 765-775
CrossRef416
Jonathan Soboloff, Yicheng Zhang, Mark Minden, Stuart A Berger. (2002) Sensitivity of myeloid leukemia cells to calcium influx blockade. Experimental Hematology 30:10, 1219-1226
CrossRef417
Dorothy Pan, Craig H. Moskowitz, Andrew D. Zelenetz, David Straus, Tarun Kewalaramani, Ariela Noy, Jing Qin, Julie Teruya-Feldstein, Carol S. Portlock. (2002) Rituximab for Aggressive Non-Hodgkin??s Lymphomas Relapsing After or Refractory to Autologous Stem Cell Transplantation. The Cancer Journal 8:5, 371-376
CrossRef418
P.A. Fields, A.H. Goldstone. (2002) Non-Hodgkin's lymphomas: clinical governance issues. Best Practice & Research Clinical Haematology 15:3, 577-596
CrossRef419
Ama Z.S. Rohatiner. (2002) High-dose treatment with autologous haemopoietic progenitor cell support for large B-cell, follicular and mantle-cell lymphoma. Best Practice & Research Clinical Haematology 15:3, 467-480
CrossRef420
CHRIS THEODOSSIOU, PAUL SCHWARZENBERGER. (2002) Non-Hodgkin's Lymphomas. Clinical Obstetrics and Gynecology 45:3, 820-829
CrossRef421
Louis M. Pelus, Daniel Horowitz, Scott C. Cooper, Andrew G. King. (2002) Peripheral blood stem cell mobilization. Critical Reviews in Oncology/Hematology 43:3, 257-275
CrossRef422
P. Schlenke, Sara Sheikhzadeh, H. Kirchner. (2002) Laboratory Parameters for Monitoring Hematopoietic Engraftment and Immune Reconstitution after Autologous Stem Cell Transplantation/Laboruntersuchungen zur Verlaufsbeurteilung der hämatologischen und immunologischen Rekonstitution nach autologer Stammzelltransplantation. LaboratoriumsMedizin 26:7-8, 399-407
CrossRef423
Andries R. Jonkhoff, Arne M. de Kreuk, Gaby Franschman, Johannes van der Lelie, Gerrit J. Schuurhuis, Angelika M. Drager, Sonja Zweegman, Peter C. Huijgens, Gert J. Ossenkoppele. (2002) Granulocyte colony-stimulating factor mobilized whole blood containing over 0.3 x 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin's lymphoma. British Journal of Haematology 118:1, 90-100
CrossRef424
Michio Sawada, Hisashi Tsurumi, Toshiki Yamada, Takeshi Hara, Kenji Fukuno, Hideko Goto, Masahito Shimizu, Senji Kasahara, Takeshi Yoshikawa, Nobuhiro Kanemura, Masami Oyama, Tsuyoshi Takami, Hisataka Moriwaki. (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. European Journal of Haematology 68:6, 354-361
CrossRef425
R Pettengell, Nnenna Osuji. (2002) Growth factors in haematological cancers. Expert Opinion on Emerging Drugs 7:1, 175-188
CrossRef426
Ikuo Murohashi, Takuya Kashimura, Kazunori Tominaga, Daisuke Wakao, Takashi Takahashi, Miki Akiba, Kuniya Kishimoto, Katsuhiko Yoshida, Fumiharu Yagasaki, Yoshihiro Itoh, Tohru Sakata, Nobutaka Kawai, Katsurou Itoh, Toshiya Suzuki, Akira Matsuda, Kunitake Hirashima, Masami Bessho. (2002) Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas. Leukemia Research 26:3, 229-234
CrossRef427
Hui-qiang Huang, Wen-qi Jiang, You-jian He, Xiao-fei Sun, Dong-geng Liu, Rui-hua Xu, Li Zhang, Zhong-mei Zhou, Tong-yu Lin, Yu-hong Li, Zhong-zhen Guan. (2002) The preliminary results of treatment ofadvanced and recurrent malignant lymphoma by beac regimen supported with autologous hematopoietic stem cells transplantation. Chinese Journal of Cancer Research 14:1, 50-53
CrossRef428
Nicolas Mounier, Gérard Socié, Christian Gisselbrecht. (2002) High-dose therapy for indolent lymphoma. Critical Reviews in Oncology/Hematology 41:2, 225-239
CrossRef429
Alberto Ballestrero, Fabio Ferrando, Maurizio Miglino, Marino Clavio, Roberta Gonella, Anna Garuti, Raffaella Grasso, Riccardo Ghio, Enrico Balleari, Marco Gobbi, Franco Patrone. (2002) Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma. European Journal of Haematology 68:2, 101-106
CrossRef430
Thierry Philip, Pierre Biron. (2002) High-dose chemotherapy and autologous bone marrow transplantation in diffuse intermediate- and high-grade non-Hodgkin lymphoma. Critical Reviews in Oncology/Hematology 41:2, 213-223
CrossRef431
John F. Seymour, Andrew P. Grigg, Jeff Szer, Richard M. Fox. (2002) Cisplatin, fludarabine, and cytarabine. Cancer 94:3, 585-593
CrossRef432
Murray S. Webb, David L. Saltman, Joseph M. Connors, James H. Goldie. (2002) A Literature Review of Single Agent Treatment of Multiply Relapsed Aggressive Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 43:5, 975-982
CrossRef433
Michael Crump, Stephen Couban, Ralph Meyer, Leona Rudinskas, Brent Zanke, Stefan Gluck, Andrew Maksymiuk, Paul Hoskins, Sarah Matthews, Elizabeth Eisenhauer. (2002) Phase II Study of Sequential Topotecan and Etoposide in Patients with Intermediate Grade Non-Hodgkin's Lymphoma: A National Cancer Institute of Canada Clinical Trials Group Study. Leukemia & Lymphoma 43:8, 1581-1587
CrossRef434
Zeev Estrov, Yang O. Huh, Cheryl F. Ginsberg, David Harris, Quin Van, Nadeem Q. Mirza, Moshe Talpaz, Martin Korbling. (2002) Ex vivo expansion of apheresis-derived peripheral blood hematopoietic progenitors. Journal of Clinical Apheresis 17:1, 7-16
CrossRef435
Marc C. Chamberlain, Craig P. Nolan, Lauren E. Abrey. (2002) Lymphomatous Meningitis. American Journal of Cancer 1:6, 423-434
CrossRef436
Jun Ooi, Tohru Iseki, Kiyoshi Ito, Yuichi Mori, Hiroyuki Sato, Tsutomu Takahashi, Koji Ishii, Akira Tomonari, Arinobu Tojo, Kenzaburo Tani, Shigetaka Asano. (2002) Successful Unrelated Cord Blood Transplantation for Relapse after Autologous Transplantation in Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 43:3, 653-655
CrossRef437
Jeff Schriber. (2002) Treatment of Aggressive Non-Hodgkin??s Lymphoma with Chemotherapy in Combination with Filgrastim. Drugs 62:Supplement 1, 33-46
CrossRef438
Ian Chau, Andrew Webb, David Cunningham, Mark Hill, Sheela Rao, Suad Ageli, Andrew Norman, Kairen Gill, Anne Howard, Daniel Catovsky. (2001) An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. British Journal of Haematology 115:4, 786-792
CrossRef439
Sergio Rutella, Luca Pierelli, Giuseppina Bonanno, Andrea Mariotti, Simona Sica, Federica Sorà, Patrizia Chiusolo, Giovanni Scambia, Carlo Rumi, Giuseppe Leone. (2001) Immune reconstitution after autologous peripheral blood progenitor cell transplantation. Experimental Hematology 29:12, 1503-1516
CrossRef440
Christos Emmanouilides, Mary Territo, Jeffrey Andrey, James Mason. (2001) A Randomized Phase II Study of Amifostine Used As Stem Cell Protectant in Non-Hodgkin Lymphoma Patients Receiving Cisplatin-Based Salvage Chemotherapy Prior to Stem Cell Transplant. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 10:6, 887-893
CrossRef441
Jose Luis P
CrossRef442
Chadi Nabhan, Nancy Krett, Varsha Gandhi, Steven Rosen. (2001) Gemcitabine in hematologic malignancies. Current Opinion in Oncology 13:6, 514-521
CrossRef443
S. A. Khan, J. R. Wingard. (2001) Infection and Mucosal Injury in Cancer Treatment. JNCI Monographs 2001:29, 31-36
CrossRef444
Sergio Cortelazzo, Alessandro Rambaldi, Andrea Rossi, Elena Oldani, Michele Ghielmini, Fabio Benedetti, Corrado Tarella, Francesco Zaglio, Umberto Vitolo, Massimo Di Nicola, Enrico Pogliani, Franco Cavalli, Alessandro Massimo Gianni, Tiziano Barbui. (2001) Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. British Journal of Haematology 114:2, 333-341
CrossRef445
Jonathan W. Friedberg, Donna Neuberg, Jedidiah Monson, Haddy Jallow, Lee M. Nadler, Arnold S. Freedman. (2001) The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation 7:8, 446-453
CrossRef446
Satoko Maeda, Yoshitoyo Kagami, Michinori Ogura, Hirofumi Taji, Ritsuro Suzuki, Eisei Kondo, Shouji Asakura, Takahiro Takeuchi, Kazuhisa Miura, Manabu Ando, Shigeo Nakamura, Tatsuya Ito, Tomohiro Kinoshita, Ryuzo Ueda, Yasuo Morishima. (2001) CD34+-Selected Autologous Peripheral Blood Stem Cell Transplantation Conditioned With Total Body Irradiation for Malignant Lymphoma: Increased Risk of Infectious Complications. International Journal of Hematology 74:2, 214-221
CrossRef447
A. J. Dowling, H. M. Prince, A. Wirth, M. Wolf, E. H. Januszewicz, S. Juneja, J. F. Seymour, P. Gates, J. G. Smith. (2001) High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience. Internal Medicine Journal 31:5, 279-289
CrossRef448
Nancy L. Bartlett, Gina R. Petroni, Barbara A. Parker, Nina D. Wagner, Jon P. Gockerman, George A. Omura, George P. Canellos, M. Robert Cooper, Jeffrey L. Johnson, Bruce A. Peterson. (2001) Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma. Cancer 92:2, 207-217
CrossRef449
M. C. Foncuberta, P. J. Cagnoni, C. H. Brandts, R. Mandanas, K. Fields, H. G. Derigs, E. Reed, S. T. Sonis, J. Fay, F. LeVeque, P. Pouillart, H. Schrezenmeier, R. Emmons, E. Thiel. (2001) Topical Transforming Growth Factor-β3 in the Prevention or Alleviation of Chemotherapy-Induced Oral Mucositis in Patients with Lymphomas or Solid Tumors. Journal of Immunotherapy 24:4, 384-388
CrossRef450
Theresa Hahn, Steven N. Wolff, Myron Czuczman, Richard I. Fisher, Hillard M. Lazarus, Julie Vose, Lisa Warren, Richard Watt, Philip L. McCartby. (2001) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review. Biology of Blood and Marrow Transplantation 7:6, 308-331
CrossRef451
Nick Maisey, David Cunningham. (2001) Current therapy and future prospects in lymphoma. Expert Review of Anticancer Therapy 1:1, 29-41
CrossRef452
John Moore, P. Brooks. (2001) Stem cell transplantation for autoimmune diseases. Springer Seminars in Immunopathology 23:1-2, 193-213
CrossRef453
Jack M Lionberger, James O Armitage. (2001) Advances in the management of patients with non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 1:1, 43-52
CrossRef454
Tarun Kewalramani, Craig H. Moskowitz. (2001) Upfront transplantation for poor-risk aggressive non-hodgkin lymphoma and hodgkin’s disease: Who benefits?. Current Oncology Reports 3:3, 271-278
CrossRef455
Carmen Martı́nez, Enric Carreras, Montserrat Rovira, Álvaro Urbano-Ispizua, Jordi Esteve, Françesc Fernández-Avilés, Marı́a Perales, Susana Rives, Marta Gómez, Emilio Montserrat. (2001) Allogenic stem cell transplantation as salvage therapy for patients relapsing after autologous transplantation: experience from a single institution. Leukemia Research 25:5, 379-384
CrossRef456
Luis Villela, Armando L
CrossRef457
Christine I. Chen, Michael Crump, Richard Tsang, A. Keith Stewart, Armand Keating. (2001) Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. British Journal of Haematology 113:1, 202-208
CrossRef458
Corey Cutler, Joseph H. Antin. (2001) Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review. Stem Cells 19:2, 108-117
CrossRef459
, Kyuhei Kohda, Sumio Sakamaki, Takuya Matsunaga, Takashi Kuga, Akihito Fujimi, Yuichi Konuma, Toshiro Kusakabe, Katsuhisa Kogawa, Takehide Akiyama, Kazuhiko Koike, Yasuo Hirayama, Yutaka Sasagawa, Syuichi Nojiri, Yasuji Hirata, Takuji Nishisato, Yoshiro Niitsu. (2001) Long-Term Survival and Late-Onset Complications of Cancer Patients Treated With High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation. International Journal of Hematology 73:2, 251-257
CrossRef460
R. I. Fisher. (2001) Autologous Bone Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma: Lessons Learned and Challenges Remaining. JNCI Journal of the National Cancer Institute 93:1, 4-5
CrossRef461
Toshiyuki Takag, Takashi Saotome. (2001) Chemotherapy with Irinotecan (CPT-11), a Topoisomerase-I Inhibitor, for Refractory and Relapsed Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 42:4, 577-586
CrossRef462
Richard S. Stein, John P. Greer, Stacey Goodman, Stephen J. Brandt, David Morgan, William R. Macon, Thomas L. McCurley, Steven N. Wolff. (2001) Intensified Preparative Regimens and Allogeneic Transplantation in Refractory or Relapsed Intermediate and High Grade Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 41:3-4, 343-352
CrossRef463
Richard S. Stein, John P. Greer, Stacey Goodman, Stephen J. Brandt, David S. Morgan, William R. Macon, Thomas L. McCurley, Steven N. Wolf. (2001) Limited Efficacy of Intensified Preparative Regimens and Autologous Transplantation as Salvage Therapy in High Grade Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 40:5-6, 521-528
CrossRef464
Outi Kuittinen, Henni Ruokolainen, Taina Turpeenniemi-Hujanen. (2001) Amifostine Does not Protect Malignant Lymphoma Cell Lines from the Cytotoxic Effects of Various Chemotherapeutics in Vitro. Leukemia & Lymphoma 42:3, 507-510
CrossRef465
Catherine Wheeler, Anwar Khurshid, Joseph Ibrahim, Anthony Elias, Peter Mauch, Kenneth Ault, Joseph Antin. (2001) Incidence of Post Transplant Myelodysplasia/Acute Leukemia in Non-Hodgkin's Lymphoma Patients Compared with Hodgkin's Disease Patients Undergoing Autologous Transplantation Following Cyclophosphamide, Carmustine, and Etoposide (CBV). Leukemia & Lymphoma 40:5-6, 499-509
CrossRef466
Per H Basse, Theresa L. Whiteside, William Chambers, Ronald B. Herberman. (2001) Therapeutic Activity of NK Cells against Tumors. International Reviews of Immunology 20:3-4, 439-502
CrossRef467
J. G. Sharp, M. R. Bishop, B. Copple, T. C. Greiner, P. L. Iversen, J. D. Jackson, S. S. Joshi, E. J. Benner, S. L. Mann, A. K. Rao, J. M. Vose. (2001) Oligonucleotide Enhanced Cytotoxicity of Idarubicin for Lymphoma Cells. Leukemia & Lymphoma 42:3, 417-427
CrossRef468
D. Nachbaur, W. Oberaigner, E. Fritsch, W. Nussbaumer, G. Gast. (2001) Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience. European Journal of Haematology 66:1, 43-49
CrossRef469
G.A. Hale, G.L. Phillips. (2000) Allogeneic stem cell transplantation for the non-Hodgkin’s lymphomas and Hodgkin’s disease. Cancer Treatment Reviews 26:6, 411-427
CrossRef470
Nabil Saba, Rick Abraham, Armand Keating. (2000) Overview of autologous stem cell transplantation. Critical Reviews in Oncology/Hematology 36:1, 27-48
CrossRef471
F. E. Davies, A. C. Rawstron, G. Pratt, R. Coupe, D. Clarke, A. Lubenko, K. Short, T. J. Perren, P. J. Selby, S. Maclennan, K. Major, V. Woodhead, F. Robinson, J. A. Child, G. M. Smith, P. W. M. Johnson, G. J. Morgan. (2000) Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests. Hematological Oncology 18:3, 111-120
CrossRef472
J Walewski, JB Krzyżanowska, E Kraszewska, E Lampka, J Romejko-Jarosińska, Z Miśkiewicz, J Meder. (2000) CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma. Medical Oncology 17:3, 195-202
CrossRef473
G Enblad, K Carlson, M Bengtsson, H Hagberg. (2000) A more favourable clinical course of lymphoma relapsing after high-dose therapy: evidence of tumour heterogeneity?. Medical Oncology 17:3, 229-232
CrossRef474
Arturo Molina, Amrita Y. Krishnan, Auayporn Nademanee, Rachel Zabner, Irena Sniecinski, John Zaia, Stephen J. Forman. (2000) High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 89:3, 680-689
CrossRef475
Bernard Couderc, Jean-Pierre Dujols, Fatma Mokhtari, Jean-Luc Norkowski, Jean-Claude Slawinski, Daniel Schlaifer. (2000) The management of adult aggressive non-Hodgkin’s lymphomas. Critical Reviews in Oncology/Hematology 35:1, 33-48
CrossRef476
A.P. Haynes. (2000) What is the Role of High-Dose Therapy in the Management of Lymphoma?. Clinical Oncology 12:2, 87-92
CrossRef477
Richard Champlin, Koen Besien, Sergio Giralt, Issa Khouri. (2000) Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: Potential for nonablative preparative regimens. Current Oncology Reports 2:2, 182-191
CrossRef478
S.J. Simnett, L.A. Stewart, J. Sweetenham, G. Morgan, P.W.M. Johnson. (2000) Autologous stem cell transplantation for malignancy: a systematic review of the literature. Clinical and Laboratory Haematology 22:2, 61-72
CrossRef479
Benjamin R Tan, Nancy L Bartlett. (2000) Treatment advances in non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 1:3, 451-465
CrossRef480
P.J. Bierman. (2000) Allogeneic bone marrow transplantation for lymphoma. Blood Reviews 14:1, 1-13
CrossRef481
Jean Gabarre, Nabih Azar, Brigitte Autran, Christine Katlama, Véronique Leblond. (2000) High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. The Lancet 355:9209, 1071-1072
CrossRef482
G. M. Cull, A. P. Haynes, J. L. Byrne, G. I. Carter, G. Miflin, P. Rebello, G. Hale, H. Waldmann, N. H. Russell. (2000) Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. British Journal of Haematology 108:4, 754-760
CrossRef483
Stuart M Lichtman. (2000) Aggressive lymphoma in the elderly. Critical Reviews in Oncology/Hematology 33:2, 119-128
CrossRef484
A. Josting, M. Reiser, P. Dias Wickramanayake, U. Rueffer, A. Draube, D. Söhngen, H. Tesch, J. Wolf, V. Diehl, A. Engert. (2000) Dexamethasone, Carmustine, Etoposide, Cytarabine, and Melphalan (Dexa-BEAM) Followed by High-Dose Chemotherapy and Stem Cell Rescue - A Highly Effective Regimen for Patients with Refractory or Relapsed Indolent Lymphoma. Leukemia & Lymphoma 37:1-2, 115-123
CrossRef485
Donald W. Milligan. (2000) Secondary Leukaemia and Myelodysplasia after Autografting for Lymphoma: Is the Transplant to Blame?. Leukemia & Lymphoma 39:3-4, 223-228
CrossRef486
Claudio Dazzi, Anna Cariello, Giovanni Rosti, Marzia Argnani, Loretta Sebastiani, Emilia Ferrari, Lia Zornetta, Giuseppe Monti, Pasquale Nicoletti, Maura Baioni, Marzia Salvucci, Emanuela Scarpi, Maurizio Marangolo. (2000) Is There Any Difference in PBPC Mobilization Between Cyclophosphamide Plus G-CSF and G-CSF Alone in Patients with Non-Hodgkin's Lymphoma?. Leukemia & Lymphoma 39:3-4, 301-310
CrossRef487
Kuniaki Itoh, Tomoko Ohtsu, Yasutsuna Sasaki, Michinori Ogura, Yasuo Morishima, Masaharu Kasai, Takaaki Chou, Kouki Yoshida, Tatsuharu Ohno, Fumi Mizorogi, Naokuni Uike, Toshiaki Sai, Masafumi Taniwakf, Shuichi Ikeda, Kensei Tobinai. (2000) Randomized Comparison of Mobilization Kinetics of Circulating CD34+ Cells Between Biweekly CHOP and Dose-Escalated CHOP with the Prophylactic Use of Lenograstim (Glycosylated rHuG-CSF) in Aggressive Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 38:5-6, 521-532
CrossRef488
C.A. Uyl-De Groot, G.J. Ossenkoppele, I. Buijt, P.C. Huijgens. (1999) Stem Cell Transplantations in Patients with Malignant Lymphoma: Costs in a Dutch University Hospital in the Period 1984-1995. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 8:6, 619-625
CrossRef489
J. E. Sanders. (1999) Stem-cell transplant preparative regimens. Pediatric Transplantation 3, 23-34
CrossRef490
Angela Krackhardt, John G Gribben. (1999) Stem cell transplantation for indolent lymphoma. Current Opinion in Hematology 6:6, 388
CrossRef491
Michael Flasshove, Werner Frings, Jan K Schröder, Thomas Moritz, Jochen Schütte, Siegfried Seeber. (1999) Transfer of the cytidine deaminase cDNA into hematopoietic cells. Leukemia Research 23:11, 1047-1053
CrossRef492
Yago Nieto, Elizabeth J. Shpall. (1999) AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR SOLID TUMORS IN ADULTS. Hematology/Oncology Clinics of North America 13:5, 939-968
CrossRef493
Dhedin, Giraudier, Gaulard, Esperou, Ifrah, Michallet, Milpied, Rio, Cahn, Molina, Laporte, Guilhot, Kuentz, . (1999) Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. British Journal of Haematology 107:1, 154-161
CrossRef494
Laura J. Johnston, Sandra J. Horning. (1999) AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA. Hematology/Oncology Clinics of North America 13:5, 889-918
CrossRef495
John R. Wingard, Jan S. Moreb, Rebecca I. Gaa. (1999) High-Dose Chemotherapy with Autologous Stem Cell Rescue as a Treatment Modality for Breast Cancer. The Breast Journal 5:5, 308-318
CrossRef496
Andreas Engert, Andreas Josting, Marcel Reiser, Dietmar Söhngen, Volker Diehl. (1999) Aktueller Stellenwert der Hochdosistherapie in der Hämatologie und internistischen Onkologie. Medizinische Klinik 94:8, 431-442
CrossRef497
R. Gregory Bociek, James O. Armitage. (1999) Hodgkin’s disease and non-Hodgkin’s lymphoma. Current Opinion in Hematology 6:4, 205
CrossRef498
P. Campbell, H. Iland, J. Gibson, D. Joshua. (1999) Syngeneic stem cell transplantation for HIV-related lymphoma. British Journal of Haematology 105:3, 795-798
CrossRef499
John G Gribben. (1999) Bone marrow transplant for lymphoma: where is the field going?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1423:3, C31-C45
CrossRef500
Rolf A. Stahel, Lorenz M. Jost, Thomas Kroner, Corina Dommann-Scherrer, Robert Maurer, Christoph Glanzmann, Emanuel Jacky, Gabriella Pichert, Bernhard Pestalozzi, Borut Marincek, Christian Sauter, Hanspeter Honegger. (1999) A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission. British Journal of Haematology 104:4, 763-769
CrossRef501
Giorgio Lambertenghi Deliliers, Claudio Annaloro, Ermanno Pozzoli, Alessandro Oriani, Aldo Della Volpe, Davide Soligo, Daniela Lambertenghi Deliliers, Elena Tagliaferri, Vanda Bertolli, Lorenza Romitti. (1999) Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantation. Leukemia Research 23:3, 291-297
CrossRef502
Maria Teresa Voso, Stefan Hohaus, Marion Moos, Margit Pforsich, Friedrich W. Cremer, Richard F. Schlenk, Simona Martin, Ute Hegenbart, Hartmut Goldschmidt, Rainer Haas. (1999) Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. British Journal of Haematology 104:2, 382-391
CrossRef503
P. Bojko, W. Stellberg, C. K
CrossRef504
O. Hermine. (1999) Hématologie. La Revue de Médecine Interne 20:1, 74-80
CrossRef505
Todd M. Zimmerman, Glenn C. Michelson, Rosemarie Mick, David L. Grinblatt, Stephanie F. Williams. (1999) Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. Journal of Clinical Apheresis 14:1, 31-34
CrossRef506
Bonfante, Viviani, Santoro, Devizzi, Di Russo, Zanini, Soncini, Soto Parra, Valagussa, Bonadonna. (1998) Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. British Journal of Haematology 103:2, 533-535
CrossRef507
KROger, Zeller, Fehse, Hassan, KRUger, Gutensohn, LOlliger, Zander. (1998) Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. British Journal of Haematology 102:4, 1101-1106
CrossRef508
Pierluigi Porcu, Craig R. Nichols. (1998) Evaluation and management of the “New” lymphoma entities: Mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma. Current Problems in Cancer 22:5, 283-368
CrossRef509
C. H. Geisler, M. Mørk Hansen, N. S. Andersen, P. Brown, L. Dalh Christensen, E. Dickmeiss, J. Ersbøll, J. Myhre, M. Hansen, B. Ravn Juhl, B. Thing Mortensen, J. Pedersen-Bjergaard. (1998) BEAM+autologous stem cell transplantation in malignant lymphoma: 100 consecutive transplants in a single centre. Efficacy, toxicity and engraftment in relation to stem-cell source and previous treatment. European Journal of Haematology 61:3, 173-182
CrossRef510
Sjoerd Rodenhuis, Dick J Richel, Elsken van der Wall, Jan H Schornagel, Joke W Baars, Caro CE Koning, Johannes L Peterse, Jacques H Borger, Willem J Nooijen, Roel Bakx, Otilia Dalesio, Emiel Rutgers. (1998) Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. The Lancet 352:9127, 515-521
CrossRef511
Charles H. Weaver, Bo Zhen, Lee Schwartzberg, Cynthia Walker, Sue Upton, C. Dean Buckner. (1998) A Randomized Trial of Mobilization of Peripheral Blood Stem Cells With Cyclophosphamide, Etoposide, and Granulocyte Colony-Stimulating Factor With or Without Cisplatin in Patients With Malignant Lymphoma Receiving High-Dose Chemotherapy. American Journal of Clinical Oncology 21:4, 408-412
CrossRef512
N Milpied. (1998) Le traitement des lymphomes agressifs de l'adulte. La Revue de Médecine Interne 19, 21S-22S
CrossRef513
, Nicolas Mounier, Pierre Morel, Corinne Haioun, Bertrand Coiffier, Herve Tilly, Christian Chatelain, Pierre Lederlin, Antoine Thyss, Raoul Herbrecht, Christian Gisselbrecht, Eric Lepage. (1998) A multivariate analysis of the survival of patients with aggressive lymphoma. Cancer 82:10, 1952-1962
CrossRef514
Emile Salloum, Anand P. Jillella, Rajani Nadkarni, Stuart Seropian, Grace L. Hu, Elizabeth D'Andrea, Daniel Zelterman, Dennis L. Cooper. (1998) Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer 82:8, 1506-1512
CrossRef515
R.E. PUGH, M.A. BITTER, E.J. SHPALL, L.S. HAMI, D.M. WOLF, W.A. FRANKLIN. (1998) CD19 Selection Improves the Sensitivity of B Cell Lymphoma Detection. Journal of Hematotherapy 7:2, 159-168
CrossRef516
Hans Tesch, Heribert Bohlen, Jürgen Wolf, Andreas Engert. (1998) Pathogenese und Therapie des Hodgkin-Lymphoms. Medizinische Klinik 93:2, 82-90
CrossRef517
M. Back, G. Delaney, J. Denham, P. Graham, C. Hamilton, G. Morgan, P. O'Brien, P. Yuile. (1998) HOW SHOULD WE INTRODUCE HIGH-DOSE CHEMOTHERAPEUTIC STRATEGIES INTO THE ADJUVANT MANAGEMENT OF HIGH-RISK BREAST CANCER IN AUSTRALASIA?. ANZ Journal of Surgery 68:1, 10-15
CrossRef518
Hillard M. Lazarus. (1998) Clinical Trial: Hematopoietic Progenitor Cell Transplantation in Breast Cancer: Current Status and Future Directions. Cancer Investigation 16:2, 102-126
CrossRef519
StÉPhanie Oddou, Norbert Vey, Patrice Viens, ValÉRie Jeanne Bardou, Catherine Faucher, Anne Marie Stoppa, Christian Chabannon, Jacques Camerlo, RÉDa Bouabdallah, Jean Albert Gastaut, Dominique Maraninchi, Didier Blaise. (1998) Second Neoplasms Following High-dose Chemotherapy and Autologous Stem Cell Transplantation for Malignant Lymphomas: A Report of Six Cases in a Cohort of 171 Patients from a Single Institution. Leukemia & Lymphoma 31:1-2, 187-194
CrossRef520
Mandigers, Raemaekers, Schattenberg, Roovers, Bogman, van der Maazen, De Pauw, De Witte. (1998) Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma. British Journal of Haematology 100:1, 198-206
CrossRef521
Sandra J. Horning. (1997) HIGH-DOSE THERAPY AND TRANSPLANTATION FOR LOW-GRADE LYMPHOMA. Hematology/Oncology Clinics of North America 11:5, 919-935
CrossRef522
M. J. Watts, D. C. Linch. (1997) Peripheral Blood Stem Cell Transplantation. Vox Sanguinis 73:3, 135-142
CrossRef523
A.J. Croockewit, M.H. Bronchud, M.S. Aapro, M.J. Bargetzi, J. Crown, A. Gratwohl, W. Lange, H. Ludwig, G. Martinelli, R. Mertelsmann. (1997) A European perspective on haematopoietic growth factors in haemato-oncology: Report of an expert meeting of the EORTC. European Journal of Cancer 33:11, 1732-1746
CrossRef524
Hartmut Link, Hans-Jochem Kolb, Wolfram Ebell, Dieter Kurt Hossfeld, Axel Zander, Dietrich Niethammer, Hannes Wandt, Hans Grosse-Wilde, Ulrich W. Schaefer. (1997) Die Transplantation hämatopoetischer Stammzellen. Medizinische Klinik 92:9, 534-545
CrossRef525
FREDERICK M. WEEKS, GARY C. YEE, ALISON A. BARTFIELD, JOHN R. WINGARD. (1997) The True Cost of Bone Marrow Transplantation. The American Journal of the Medical Sciences 314:2, 101-112
CrossRef526
P Fenaux. (1997) Les facteurs de croissance hématopoïétiques dans le traitement des hémopathies malignes. La Revue de Médecine Interne 18:8, 668-672
CrossRef527
Rodney Maza, Helmut Hanenberg, David A. Williams. (1997) Establishing chemoresistance in hematopoietic progenitor cells. Molecular Medicine Today 3:8, 350-358
CrossRef528
Ian Wicks, Helen Cooley, Jeff Szer. (1997) Autologous hemopoietic stem cell transplantation. A possible cure for rheumatoid arthritis?. Arthritis & Rheumatism 40:6, 1005-1011
CrossRef529
Gianni, Alessandro M., Bregni, Marco, Siena, Salvatore, Brambilla, Cristina, Di Nicola, Massimo, Lombardi, Fabrizio, Gandola, Lorenza, Tarella, Corrado, Pileri, Alessandro, Ravagnani, Fernando, Valagussa, Pinuccia, Bonadonna, Gianni, . (1997) High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma. New England Journal of Medicine 336:18, 1290-1298
Full Text530
SELVA DAVID, JEAN-MICHEL BOIRON, MARYSE DUPOUY, ALISON RICE, ISABELLE VIANES, VALÉRIE DUPERRAY, JOSY REIFFERS. (1997) Expansion of Blood CD34+ Cells: Committed Precursor Expansion Does Not Affect Immature Hematopoietic Progenitors. Journal of Hematotherapy 6:2, 151-158
CrossRef531
Donna E. Salzman, Adrienne D. Briggs, William P. Vaughan. (1997) Bone Marrow Transplantation for Non-Hodgkin's Lymphoma: A Review. The American Journal of the Medical Sciences 313:4, 228-235
CrossRef532
U. Kaiser, R. Pfab, K. Havemann. (1997) Stellenwert der Strahlentherapie beim disseminierten hochmalignen Non-Hodgkin-Lymphom. Strahlentherapie und Onkologie 173:3, 136-140
CrossRef533
Frank Hartmann, Michael Pfreundschuh. (1997) Onkologie ’96. Medizinische Klinik 92:2, 83-100
CrossRef534
James R. Mason, Anthony D. Ho. (1997) Advances in Autologous Stem Cell Transplantation. Cancer Investigation 15:6, 553-560
CrossRef535
Michael R. Bishop, Anne Kessinger. (1997) Blood Stem Cell Transplantation in Non-Hodgkin's Lymphoma. Cancer Investigation 15:2, 138-142
CrossRef536
M Balzarotti. (1996) Lack of carboplatin activity in malignant lymphomas. European Journal of Cancer 32:13, 2370-2371
CrossRef537
H. Hagberg, E. Kimby. (1996) Treatment of aggressive non-Hodgkin’s lymphoma in adults — Are we doing any better?. Medical Oncology 13:4, 185-194
CrossRef538
(1996) Autologous Bone Marrow Transplantation in Relapsed Non-Hodgkin's Lymphoma. New England Journal of Medicine 334:15, 990-992
Full Text539
Thierry Philip. (1996) The Centre Leon Berard Cancer Center. Pediatric Hematology-Oncology 13:6, 477-486
CrossRef540
K. Clarke, R. L. Basser. (1996) The Role of Platelet Growth Factors in Cancer Therapy. Stem Cells 14:S1, 274-280
CrossRef541
J.A. Ledermann. (1996) Peripheral blood stem cell transplantation in common solid tumours: Passing phase or new era?. Clinical Oncology 8:4, 209-211
CrossRef542
ZS Pavletic, MR Bishop, PJ Bierman, JO Armitage. (1996) Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas. Biomedicine & Pharmacotherapy 50:3-4, 118-124
CrossRef543
Vose, Julie M., . (1995) Treatment for Non-Hodgkin's Lymphoma in Relapse — What Are the Alternatives?. New England Journal of Medicine 333:23, 1565-1566
Full Text544
George Marcoullis, Jayesh Mehta, Jennie Treleaven. (1995) Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status. Medical Oncology 12:4, 209-218
CrossRef545
Thomas D. Miale, Suebsuk Sirithorn, Syed Ahmed. (1995) Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. I: Clinical applications and therapeutic effects. Medical Oncology 12:4, 231-249
CrossRef
- Letters
